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ABSTRACT
ROLE OF THE NUCLEAR RECEPTOR PPARγ IN CLEAR CELL RENAL AND
BLADDER UROTHEIAL CARCINOMA
Danielle J. Sanchez
M. Celeste Simon, Ph.D.

The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) has a
well-characterized role in the developmental process of adipogenesis and transcriptional
regulation of lipid metabolism. However, its expression patterns and functions in various cancer
subtypes are less understood. My studies investigate the role of PPARγ in two distinct cancers of
the urinary tract: clear cell renal cell carcinoma (ccRCC) and bladder urothelial carcinoma (UC).
In ccRCC, I hypothesized that PPARγ activity contributes to the aberrant lipid accumulation
phenotype characteristic of this disease, thereby promoting tumor progression. Through ChIPseq, I demonstrated that PPARγ and its heterodimeric DNA binding partner retinoid X receptor
(RXR) occupy both adipose-shared and ccRCC-specific sites throughout the genome. However,
based on a number of in vitro and in vivo assays evaluating ccRCC viability, proliferation,
migration, and effects on lipid metabolism, I concluded that PPARγ was dispensable for these
processes and ccRCC progression. I also studied the role of PPARγ in UC, a cancer which
displays copy number amplification and mRNA overexpression of PPARG or RXRA in ~30% of
tumors. In contrast to the results obtained in ccRCC, I demonstrated that genetic and
pharmacological inhibition of PPARγ reduces tumor growth via cell cycle arrest. Furthermore, I
identified a candidate list of PPARγ-regulated genes in UC based on ChIP- and RNA-seq
analyses of cell culture models, as well as gene expression data from primary patient samples.
Together, my studies illuminate the remarkable cell type-specific functions of PPARγ in urinary
tract cancers, and provide rationale for the pharmacological targeting of its transcriptional
effectors in a subset of tumors.
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Chapter 1: General Introduction

A portion of this chapter has been adapted with modifications from: Sanchez, DJ, Simon, MC.
Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochim Biophys Acta Rev
Cancer. 2018 Aug;1870(1):23-31. doi: 10.1016/j.bbcan.2018.06.003.
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1.1 Introduction to nuclear receptors and the peroxisome proliferator-activated receptor
gamma (PPARγ)
Nuclear receptor structure and mechanism of action
Nuclear receptors (NRs) are a family of ligand-activated transcription factors that couple
metabolic cues from the external environment to the regulation of gene expression. The human
genome encodes 48 NRs, many of which were initially classified as “orphan” receptors, as their
activating ligands and physiological functions were unknown (Chawla et al., 2001b). NRs share
common structural domains, including an N-terminal regulatory domain containing a ligandindependent transcriptional activation function (AF-1); DNA-binding domain composed of two zinc
finger motifs; hinge region, and a large C-terminal region containing the ligand-binding domain;
dimerization region; and ligand-dependent activation function (AF-2) (Tsai and O'Malley, 1994).
Type I NRs are located in the cytosol and bound to chaperone proteins in the absence of ligand.
Upon ligand-binding, these NRs dissociate from chaperones, homodimerize, and translocate to
the nucleus to activate target gene expression. Type II NRs, such as PPARs, are generally bound
on DNA as heterodimers regardless of activation state (Sever and Glass, 2013). Briefly, ligandbinding induces a conformational change that dissociates co-repressor molecules and facilitates
binding of co-activators. NR co-activator proteins contain intrinsic histone acetyltransferase
activity to facilitate chromatin decondensation, while co-repressors recruit histone deacetylase to
compact chromatin (Dasgupta et al., 2014). CBP/p300, the SRC family, TRAP220 (MED1), and
PGC-1α all function as NR co-activators; silencing mediator for retinoid and thyroid hormone
receptors (SMART), nuclear receptor co-repressor (NCoR), and RIP140 are co-repressors (Hu
and Lazar, 1999; Tontonoz and Spiegelman, 2008).

Peroxisome proliferator-activated receptors
The peroxisome proliferator-activated receptor (PPAR) family are type II NRs and contain
three members: PPARα, PPARδ, and PPARγ. PPARs have distinct tissue expression patterns
and biological functions, but are all broadly important for the regulation of lipid metabolism and
2

	
  

energy homeostasis. The retinoid X receptor (RXR) is the heterodimeric partner of PPAR
transcription factors, which together bind a consensus motif containing a hexameric DNA
sequence repeated with a single nucleotide spacer AGGTCA(N)AGGTCA (known as DR1)	
  
(Kliewer et al., 1992). PPARα is a critical regulator of fatty acid catabolism and lipoprotein
assembly, and is most highly expressed in the liver, kidney, and heart (Mandard et al., 2004).
PPARδ is expressed ubiquitously and has also been implicated in fatty acid oxidation, although
the specific biological functions of this family member are the least studied of the three (Luquet et
al., 2005). PPARγ is the master regulator of adipogenesis (discussed below), and is expressed in
fat cells as PPARγ1 and PPARγ2, isoforms that differ by 30 amino acids at the N-terminus of the
protein. This is achieved through alternative promoter usage and differential splicing of the mRNA
transcript (Fajas et al., 1997; Zhu et al., 1995). PPARG expression in non-adipocyte cells
predominantly results in the production of the PPARγ1 isoform. Endogenous ligands of PPARγ
include polyunsaturated fatty acids, prostanoids such as 15-deoxy-Δ12–14-PGJ2, and the
oxidized fatty acids 9-hydroxyoctadecadienoic acid (HODE) and 13-HODE. However, the identity
of the biological ligand(s) important for PPARγ activation in vivo remains unknown (Sauer, 2015;
Tontonoz and Spiegelman, 2008). Post-translational modifications can also change the activity of
the receptor, such as phosphorylation of mPPARγ2 at serine 112 by mitogen-activated protein
kinase (MAPK), which decreases its transcriptional activity by inhibiting ligand binding (Adams et
al., 1997; Hu et al., 1996; Shao et al., 1998).

1.1a Roles of PPARγ in development and metabolic disease
PPARγ works coordinately with CCAAT-enhancer-binding proteins (C/EBP) alpha and
beta to direct the terminal differentiation of mesenchymal stem cell-derived precursors into
adipocytes. Specifically, hormonal treatment of preadipocytes induces C/EBPβ/δ, which binds to
the promoter of PPARG and activates its expression (Wu et al., 1996; Wu et al., 1995). PPARγ
then induces C/EBPα, which participates in a positive-feedback loop with its activator to drive the
3

	
  

expression of genes important for triglyceride uptake and storage (Rosen et al., 2002). As
C/EBPα cannot promote adipogenesis in the absence of PPARγ, the latter is considered the
“master regulator” of adipogenesis and has been shown to be both necessary and sufficient for
this process in vitro (Tontonoz et al., 1994) and in vivo (Wang et al., 2013).
Since homozygous knockout of PPARG results in embryonic lethality (Barak et al., 1999),
several groups have created conditional, adipose-specific deletions of PPARG in mice to
investigate its function postnatally. Early studies from the Evans group reported progressive
-/-

lipodystrophy in an FABP4 driven (ap2-Cre) PPARG model, which was accompanied by
hyperlipidemia, fatty liver (hepatosteatosis), and hepatic insulin resistance (He et al., 2003).
These results were corroborated by tamoxifen-inducible PPARG deletion in mature white and
brown adipocytes, which died within a few days of knockout and were replaced by newly
differentiated PPARγ-positive adipocytes (Imai et al., 2004). A more dramatic phenotype was
observed using an independent Cre-driver of PPARG deletion in fat by the adiponectin promoter
(Aqipoq-Cre) (Wang et al., 2013). These results from mouse models are also supported by
studies of polymorphisms linked to human metabolic disease. For example, heterozygous,
R425C mutation of PPARG was reported in a patient with familial partial lipodystrophy (Agarwal
and Garg, 2002). Collectively, these data demonstrate the critical role for PPARγ in mammalian
adipose tissue development and function throughout the lifespan.
Metabolic syndrome is a collection of symptoms including obesity, hyperlipidemia,
hypertension, insulin resistance, and hepatosteatosis, all of which are influenced by the “Western”
diet, genetics, and sedentary lifestyle.	
  Collectively, type 2 diabetes and other metabolic diseases
pose a significant health risk for both adults and children in the United States, and incidence has
been rising dramatically over the past decades (Eckel et al., 2005). The synthetic PPARγ agonists
thiazolidinediones (TZDs) are one class of medication commonly used for the treatment of type 2
diabetes. TZDs exert pleiotropic effects on a number of tissues, but are thought to predominantly
work by activating PPARγ function in adipocytes (Yki-Jarvinen, 2004). Proposed mechanisms of
TZD action include increasing small adipocyte number and increasing fatty acid uptake into
4

	
  

adipose tissue, thereby preventing it from being deposited in ectopic tissues such as the liver
(Okuno et al., 1998).
As PPARG is expressed at low levels in muscle and macrophages, conditional deletion
studies have also been performed to elucidate its role in development and pathology in these
tissues. PPARG knockout using muscle creatine kinase (MCK-Cre) results in insulin resistance in
muscle, and can induce secondary effects in whole-body metabolism including
hypertriglyceridemia (Hevener et al., 2003). While PPARG is normally expressed at very low
levels in hepatocytes, PPARγ protein levels increase in livers of high-fat diet treated mice, and
hepatocyte-specific PPARG knockout reduces lipid accumulation in this model (Morán-Salvador
et al., 2011). PPARG expression is also much lower in macrophages than in adipose tissue, yet it
plays an important function in regulating lipid uptake and the activation of anti-inflammatory
pathways (Chawla et al., 2001a; Lefterova et al., 2010; Nelson et al., 2018). In an injury model of
cardiac hypertrophy, PPARγ was shown to be involved in fatty acid uptake and the regulation of
glycerolipid biosynthesis genes within cardiomyocytes	
  (Krishnan et al., 2009). These data from
mouse models support a role for PPARγ in the regulation of lipid metabolism in adipocytes as well
as other tissues (e.g., liver, macrophages), particularly during conditions of metabolic disease and
related pathologies.

1.1.b Roles of PPARγ in cancer
PPARγ has been traditionally described as having tumor suppressive functions in a
variety of mouse models of cancer, although studies suggest that this is highly dependent on
cell/tissue of origin, as well as the specific genetic and carcinogenic drivers of each subtype.
Heterozygous deletion of PPARG in chemically-induced models of colorectal and breast cancer
increases tumorigenesis and decreases survival time compared to wildtype controls (Girnun et
al., 2002; Nicol et al., 2004). However, two other studies in an Apc

Min/+

driven model

demonstrated that troglitazone and rosiglitazone (TZD) treatment increased the frequency and
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size of polyps, suggesting oncogenic functions for PPARG in this background (Lefebvre et al.,
1998; Saez et al., 1998).
Due to the potency of TZDs in inducing terminal adipocyte differentiation (accompanied
by cell cycle arrest), it was hypothesized that these drugs could be useful in halting cancer cell
growth. Indeed, anti-proliferative effects of TZDs were particularly pronounced in liposarcomas,
tumors which are derived from a cell-of-origin in the mesenchymal lineage and express levels of
PPARγ nearly equivalent to adipocytes (Tontonoz et al., 1997). However, most in vitro studies
examining the relationship between TZDs and cancer proliferation involve doses in the
micromolar range, concentrations associated with “off-target” effects on cellular processes
including inhibition of the p38 MAPK pathway and inhibiting the anti-apoptotic functions of Bcl-2
and Bcl-xL independently of PPARγ (Fujita et al., 2011; Shiau et al., 2005). TZDs were reportedly
effective in reducing xenograft tumor growth of lung adenocarcinoma cells, yet endogenous levels
of PPARγ in lung adenocarcinoma cells were not demonstrated in that publication	
  (Srivastava et
al., 2014). A careful analysis of PPARγ protein abundance and expression patterns throughout
the course of disease progression will be a useful first step in determining whether it provides
oncogenic or tumor suppressor functions in a given cancer model.
To that end, our curated data from publicly available sources suggest that PPARγ might
play an important biological role in other cancer subtypes where it is expressed appreciably. For
example, analyses of mRNA expression patterns and sensitivity of cancer cell lines to PPARG
CRISPR knockout show that pancreatic cancer cell lines have the highest expression of the gene
among all cell lines profiled (Figure 3.1E) and that these cell lines may be sensitive to its
inhibition (Figure 3.4E). Based on these data, we speculate that pancreatic adenocarcinoma may
be another cancer dependent on PPARγ signaling for growth, although this remains to be
determined experimentally.
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1.2 Introduction to clear cell renal cell carcinoma (ccRCC)
th

Kidney cancer is the 8 most prevalent cancer diagnosed each year in the United States, with
an estimated 64,000 new cases in 2017 (Institute, 2018). The median age at diagnosis for both
sexes is 64, and total overall incidence rate has been increasing over the past decade. Clear cell
renal cell carcinoma (ccRCC) accounts for 70-80% of kidney cancer diagnoses, and represents
the most aggressive subtype of this disease (Rini et al., 2009). Risk factors for ccRCC include
smoking, obesity, von Hippel-Lindau (VHL) disease (defined below), and hypertension. If disease
is detected early and still localized within the kidney, surgical resection or nephrectomy is
performed with a 5-year survival rate of ~92%. However, if the tumor has spread locally or
systemically, 5-year survival rates drop to 67% or 12%, respectively, due to limitations in current
standard-of-care therapies for metastatic disease (Institute, 2018).
A defining morphological hallmark of ccRCC is robust lipid and glycogen accumulation in
the cytoplasm of tumor cells, giving rise to the name “clear cell”. Widespread metabolic
reprogramming in glucose, lipid, and amino acid metabolism broadly contributes to the clear cell
phenotype (Wettersten et al., 2017), although the advantages conferred unto tumor cells
harboring these adaptations are incompletely understood. Compared with other solid tumors
driven by loss of classical tumor suppressors or activation of oncogenes (e.g., those encoding
p53 and K-Ras), ccRCC has been labeled as a “metabolic disease” supported by alterations in
myriad bioenergetic pathways (Hakimi et al., 2013b; Linehan et al., 2010). Genetic hallmarks
include biallelic inactivation of the VHL tumor suppressor gene, the negative regulator of hypoxiainducible factor (HIF) proteins, as well as copy number alterations of chromosome 3p, 5q, and
14q genes, and high frequency of mutation in chromatin modifying enzymes (e.g., PBRM1,
SETD2, and BAP1). Here, we discuss recent advances in ccRCC research related to elucidating
the underlying genetic drivers of human disease, progress on obtaining an autochthonous,
genetically engineered mouse model (GEMM) for pre-clinical studies, metabolic reprogramming,
and therapeutic strategies moving forward.
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1.2.a Genetics of ccRCC
VHL loss and HIF-α stabilization
The most common genetic event of ccRCC is copy number deletion, inactivating
mutation, and/or epigenetic silencing of VHL (encoding pVHL), the recognition component of an
E3-ubiquitin ligase complex responsible for targeting HIF-1α and HIF-2α for proteasomal
degradation under normoxic conditions (Figure 1.1). VHL disease is a familial disorder marked by
increased propensity for ccRCC, retinal and cerebellar hemangioblastoma, and
pheochromocytoma development. In hereditary disease, patients inherit only one functional copy
of the VHL gene, and subsequent loss of heterozygosity (LOH) results in disease (Kaelin Jr,
2007). pVHL loss results in constitutive stabilization of HIF-α subunits even under oxygen-replete
conditions, which translocate to the nucleus and heterodimerize with HIF-1β (ARNT) (Keith et al.,
2012). HIFs transcriptionally activate numerous genes involved in cellular processes including
glycolysis, angiogenesis, and metastasis of cancer cells (Mucaj et al., 2012). Notably, while VHL
inactivation occurs in upwards of 90% of all patients, its loss alone is insufficient to generate
ccRCC tumors (Mandriota et al., 2002; Nickerson et al., 2008). Characterization of HIF-α protein
accumulation in ccRCC has revealed distinct patterns; ~10% retain wildtype VHL and express
neither HIF-1α nor HIF-2α, ~60% of tumors express both HIF-1α and HIF-2α, and ~30% express
HIF-2α alone (Gordan et al., 2008). This can occur as a result of loss of chromosome 14q as
disease advances, on which the HIF1A gene resides (Kaku et al., 2004; Shen et al., 2011).
Indeed, HIF-1α has been linked with tumor suppressive functions in ccRCC (Shen et al., 2011),
(Zhang et al., 2007), while HIF-2α has been established as a dominant oncogenic driver of
disease progression (Gordan et al., 2007; Kondo et al., 2003; Kondo et al., 2002; Raval et al.,
2005). These observations have supported efforts to develop small molecule antagonists of HIF2α, which are currently being tested in clinical trials for the treatment of metastatic ccRCC
(Martínez-Sáez et al., 2017), and will be discussed later.
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Copy number and single nucleotide variation
Recent sequencing studies involving large cohorts of ccRCC patients have revealed
signatures of copy number amplification and deletion across the tumor genome (Beroukhim et al.,
2009), (Dondeti et al., 2012). A 43 megabase region of chromosome 3p contains multiple bona
fide or putative tumor suppressor genes including VHL, PBRM1, BAP1, and SETD2 (discussed
below) (Peña-Llopis et al., 2013). Mechanistically, this gene inactivation occurs on one allele
through intergenic point mutation, and on the second allele through LOH (Gerlinger et al., 2012)
(Gerlinger et al., 2014). On a genome-wide scale, copy number variation of the following regions
are most abundant in ccRCC tumors: chromosome 3p loss (91%), 5q gain (67%), and 14q loss
(49%) (Network, 2013).
While chromosome 3p and 14q genes are generally associated with having tumor
suppressive functions in ccRCC, copy number amplification of a ~60 gene region of chromosome
5q35 harbors candidate oncogenes (Dondeti et al., 2012; Network, 2013). SQSTM1, which
encodes the p62 protein involved in activation of NRF2 and resistance to oxidative stress, was
shown to be a chromosome 5q gene frequently amplified in ccRCC patient samples and cell lines
(Li et al., 2013). Suppression of p62 decreased resistance to redox stress and soft agar colony
formation in vitro and xenograft tumor growth in vivo. Additionally, siRNA-mediated suppression
of SQSTM1 reduced mechanistic target of rapamycin (mTOR) signaling, a key nutrient sensing
pathway involved in the regulation of cell proliferation, protein synthesis, and autophagy,
suggesting multiple mechanisms by which p62 promotes ccRCC progression (Duran et al., 2011).
Other work has implicated the chromosome 5q genes EZH2, STC2, and VCAN, which were all
copy number gained and overexpressed at the mRNA level, as having oncogenic functions in
ccRCC (Dondeti et al., 2012), (Liu et al., 2016). These data suggest that the chromosome 5q
hotspot of gene duplication may contain several clinically relevant targets.
Genome-wide association studies (GWAS) have also been conducted in ccRCC patients
to illuminate single nucleotide variants predisposing individuals to the disease. A 2017 study
identified seven new susceptibility loci, including a single nucleotide polymorphism (SNP) within a
9

	
  

predicted intronic enhancer of DPF3, a histone acetylation and methylation reader protein of the
BRG1-associated factor (BAF) 180 and polybromo-BAF (PBAF) chromatin remodeling complexes
(Scelo et al., 2017). Interestingly, the location of this SNP (14q24) is deleted in one quarter to half
of patients (Scelo et al., 2014), and dysregulation of other components of BAF and PBAF
complexes are common features of ccRCC. The same group also identified BHLHE41, a gene
encoding a basic helix-loop-helix protein located in the 12p12.1 susceptibility locus, from GWAS
(Bigot et al., 2016). The ccRCC risk allele associated with this gene increased its expression, and
the authors provided functional evidence that ectopic expression of BHLHE41 increased
xenograft tumor growth.
An earlier GWAS identified two SNPs associated with RCC susceptibility within a 4.2 kb
region of the first intron of EPAS1 (encoding HIF-2α) as well as another at 11q13.3, which is not
localized intergenically but flanks MYEOV and CCND1 (encoding cyclin D1) (Purdue et al., 2011).
Additional work demonstrated that the risk SNP at this CCND1 enhancer promoted HIF-2α
binding, thereby increasing the mRNA expression of this oncogenic cell cycle regulator (Schödel
et al., 2012). The variants within EPAS1 are also notable as HIF-2α inhibition has been
repeatedly demonstrated to reduce ccRCC growth (Kondo et al., 2003; Kondo et al., 2002; Qiu et
al., 2015). However, the functional relationship between intronic EPAS1 SNPs and its mRNA
expression was not determined. A study of familial renal cell carcinoma identified mutations in the
CDKN2B gene through exon sequencing as predisposing individuals to tumor development (Jafri
et al., 2015). CDKN2B encodes the p15

INK4B

protein, which normally functions as a tumor

suppressor by binding and inhibiting cyclin-dependent kinases 4 and 6 to prevent cell cycle
progression (Roussel, 1999). These mutations, which germline-inactivated CDKN2B in 5% of
patients, were predicted to destabilize the interaction between p15
Furthermore, expression of wildtype p15

INK4B

INK4B

and the CDKs.

in vitro was shown to suppress colony formation

relative to the mutant isoforms, providing support for its ability to act as a tumor suppressor in
ccRCC.
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Perhaps not unexpectedly, subclonal heterogeneity is a common feature within ccRCC
tumors (Gerlinger et al., 2014). Such variation manifests as spatially separated mutational
patterns and chromosomal imbalances, which create a range of intratumoral phenotypes. For
example, gene expression patterns associated with both good and poor prognoses can be found
rd

within the same tumor, and roughly 2/3 of all somatic mutations are not detectable in every
sequenced region (Gerlinger et al., 2012). The degree to which clonal heterogeneity affects
disease progression and informs treatment strategies will be an important consideration for both
researchers and clinicians moving forward. Nevertheless, additional studies on copy number and
single nucleotide variation may help elucidate the etiology of ccRCC, as well as identify new
therapeutic targets of interest.

Histone and chromatin modifying enzyme mutations
After mutation of VHL (53% of patients), PBRM1, SETD2, and BAP1 are the most
commonly mutated genes in ccRCC at 40%, 13%, and 10% of patients, respectively (Turajlic et
al., 2015). PBRM1 encodes BAF180, which is the defining subunit of the PBAF switch/sucrose
non-fermentable (SWI/SNF) chromatin remodeling complex which uses ATP for nucleosome
repositioning (Varela et al., 2011). Varela, et al. demonstrated that suppression of PBRM1
through siRNA resulted in enhanced proliferation, colony formation, and migration of several
ccRCC cell lines in vitro, consistent with a tumor suppressive function in renal carcinoma (Varela
et al., 2011). Interestingly, Gao, et al. did not recapitulate these in vitro findings, but found that
PBRM1 suppression by CRISPR did promote subcutaneous tumor growth in an on-target fashion
(Gao et al., 2017). Inactivating or truncating mutations in JARID1C (also known as KDM5C), a
histone H3 lysine 4 demethylase, and UTX (KMD6A) a histone H3 lysine 27 demethylase were
identified in another study as positively selected for in ccRCC compared to other cancers
(Dalgliesh et al., 2010; Van Haaften et al., 2009). Depletion of SETD2, the histone H3 lysine 36
tri-methyltransferase catalyzing methylation at sites of active transcription, was associated with
DNA replication stress and reduced loading of nucleosome components onto chromatin (Kanu et
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al., 2015). The authors speculated that SETD2 loss of function during disease progression could
be a source of genomic instability and heterogeneity within ccRCC. BAP1, a deubiquitinating
enzyme involved in transcriptional repression of genes as a polycomb-group protein, exhibits
mutations that are largely mutually exclusive with PBRM1 (Guo et al., 2012). How
hypermethylation of enhancer and promoter CpG regions affects ccRCC progression is an
ongoing area of investigation in the field (Shenoy et al., 2015).

1.2.b Genetic mouse models of renal cell carcinoma
Tumor suppressor deletion
As VHL deletion is insufficient to drive ccRCC tumorigenesis (Rankin et al., 2006),
conditional knockout mice have been generated in several laboratories combining deletion of
candidate tumor suppressor genes based on large-scale patient sequencing data (Network, 2013;
Sato et al., 2013). A recent report combined Vhl and Pbrm1 deletion throughout renal tubules,
collecting ducts, and thick ascending limbs using Ksp-Cre (Shao et al., 2002), and found that 67%
of these mice first developed polycystic kidney disease (PKD) within 10-14 months of age
(Nargund et al., 2017). While deletion of either gene alone did not result in PKD or ccRCC, 50%
-/-

-/-

of the double knockout (Vhl , Pbrm1 ) mice showed signs of tumor incidence after 10 months of
age, with clear cell morphology, activated mTOR signaling, and reduction in oxidative
phosphorylation gene signatures reported. Notably, while the primary tumors were orthotopically
-/-

-/-

transplantable into NSG mice, metastatic tumor burden was not detected in Vhl , Pbrm1 mice.
Though TP53 deletion or mutation is relatively uncommon in human ccRCC tumors,
another study examined the effect of conditional Vhl, Trp53, and Rb1 loss in the renal epithelium
(utilizing Ksp-Cre), as changes in regulators of the p53 pathway and the G1/S cell cycle transition
are frequently copy number modified according to The Cancer Genome Atlas (TCGA) data
(Harlander et al., 2017). The authors found evidence of tumor onset as early as 7.5 months
following triple knockout in a subset of mice, which were characterized by HIF-α and mTORC1
pathway activation by carbonic anhydrase 9 and phospho-4E-BP1 immunostaining, respectively.
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-/-

-/-

-/-

Further analyses of a larger cohort suggested 82% of Vhl , Trp53 , Rb1 mice developed
tumors within 15 months of gene deletion, the majority of which were classified as grade 3 or 4
tumors growing in acinar or pseudo-papillary patterns. These renal tumors had clear or weakly
stained cytoplasm, and displayed gene expression and mutational signatures similar to human
-/-

-/-

-/-

st

ccRCC. While some Vhl , Trp53 , Rb1 tumors were sensitive to 1 and 2

nd

line chemotherapies

rd

sunitinib and everolimus, nearly all were resistant to 3 line treatment with acriflavine, the panHIF-α inhibitor (Lee et al., 2009). These results mimic the variability in drug responsiveness
-/-

-/-

-/-

typical of the human disease. Similar to Vhl and Pbrm1 co-deletion, Vhl , Trp53 , Rb1 mice
developed tumors which remained localized within the kidney.
Consistent with chromosome 3p genes displaying tumor suppressive functions in ccRCC,
the effect of Bap1 deletion in combination with either Vhl or Pbrm1 loss has been examined in
several publications from the Brugarolas group. Under the control of Six2-Cre driver, which is
expressed in multipotent nephron progenitor cells of the kidney during development, the authors
-/-

first generated Vhl , Bap

+/-

mice (deletion of both alleles of Vhl and one of Bap1) (Wang et al.,

2014). These mice developed kidneys with atypical cysts and neoplasia resembling those of
patients with VHL syndrome. Some of the lesions observed were similar to early-stage ccRCC
tumors by cytoplasmic clearing, Ki67 expression, and phospho-S6 positivity as a marker of
mTOR activity, yet tumors remained small overall. Again, tumors from this mouse model did not
-/-

metastasize, and Vhl , Bap1

+/-

mice died after 8 months from renal failure, suggesting that

additional events are required for ccRCC progression.
A more recent study from this group used additional Cre drivers to modulate Pbrm1 and
Bap1 levels in different lineages within the kidney. Pax8-Cre was used to delete Vhl and Bap1 or
Pbrm1 within the proximal and distal renal tubules, loops of Henle, collecting ducts, and parietal
cells of the Bowman capsule (Gu et al., 2017). Sglt2- and Villin-Cre were also used for more
specific deletion within proximal tubule epithelial cells. Tumors generated with Pax8-Cre were
larger than those generated with the Six2-Cre model investigated previously. Interestingly,
deletion of both alleles of Vhl along with a single allele of either Pbrm1 or Bap1 using Sglt2- and
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Villin-Cre drivers did not result in ccRCC formation. Based on these data, the authors speculated
that ccRCC may be derived from the parietal epithelial cells of the Bowman capsule, rather than
proximal tubule cells, as previous histologic and gene expression data would suggest (Chen et
al., 2016a; Yoshida et al., 1986). The authors also found that activation of mTORC1 signaling
through inactivation of one allele of Tsc2 caused the formation of higher grade ccRCC specifically
in Pbrm1-deficient kidneys. Notably, patients with PBRM1 and BAP1 mutations have distinct
gene expression patterns and clinical outcomes, and these alterations are largely mutually
exclusive (Kapur et al., 2013). While BAP1-deficient tumors are higher in grade and portend
worse prognosis than PBRM1-deficient tumors, it is believed that BAP1 mutations are secondary
to PBRM1 loss in the pathogenesis of ccRCC (Hakimi et al., 2013a; Peña-Llopis et al., 2012).

Oncogene activation
An early mouse model of ccRCC was generated using a constitutively active mutant of
HIF-1α, termed TRACK (transgenic model of cancer of the kidney) (Fu et al., 2011). HIF-1α
protein is found in VHL-deficient renal epithelial cells and in early tubular lesions, cysts, and
ccRCC, suggesting it is important for carcinogenesis (Rankin et al., 2006). TRACK mice
expressed a triple-mutant HIF-1α, which was insensitive to hydroxylation and therefore
degradation by the PHD/pVHL system, under the control of the γ-glutamyl transferase (GGT)
proximal tubule-specific promoter. Phenotypes included abnormal vascularization, renal cysts,
cleared cells, and high carbonic anhydrase 9 staining. A small percentage of cleared cells
accumulated γH2AX, a marker of DNA double-strand breaks, although the mechanism by which
HIF-1α led to genomic instability was not described. Even though HIF-1α exerts tumor
suppressive functions in established ccRCC, this study demonstrates it is a critical downstream
mediator of VHL loss early in disease progression. Accordingly, neither late-stage nor metastatic
disease was detected in TRACK mice.
Another two studies investigated the role of MYC overexpression in the kidney and its
role in promoting renal tumorigenesis. According to TCGA data, genomic amplification of MYC
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only occurs in about 5-10% of patients, however, the MYC/MAX transcriptional network has been
predicted to promote glycolysis, de-differentiation, and growth in a majority of ccRCC (Tang et al.,
2009). MYC pathway activation is also associated with a hereditary RCC characterized by
translocation of chromosomes 3 and 8 (Drabkin et al., 1985). Conditional overexpression of MYC,
but not KRAS, under the GGT gene promoter gave rise to a highly aggressive RCC that most
resembled collecting-duct carcinoma (Shroff et al., 2015). Combined gene expression and
metabolite analysis, along with small molecule inhibition of glutaminase, revealed a dependency
on glutamine for sustained growth of these tumors, similar to the human disease.
In another report, the combination of MYC overexpression along with further deletion of
Vhl and/or Cdkn2a (encoding Ink4/Arf) was investigated for the ability to induce papillary or clear
cell renal cell carcinoma (Bailey et al., 2017). This study utilized the Ksp promoter to drive
expression of a doxycycline-inducible Myc transgene. When MYC was overexpressed without
deletion of either Vhl or Cdkn2a, the mice developed tumors histologically consistent with
papillary RCC. However, Vhl deletion in combination with MYC overexpression (“VM”) mice
generated tumors more similar to ccRCC based on cytoplasmic clearing, necrosis, and
hemorrhage. Addition of Cdkn2a deletion to this model (“VIM”) further potentiated ccRCC
formation compared with Vhl deletion alone, increasing tumor volume and decreasing median
survival time. VIM mice had a median survival of 29.5 weeks following gene
inactivation/induction, whereas, VM mice had a median survival of 57 weeks. Importantly, 2 out of
6 VIM mice developed metastasis to the liver, and in vitro characterization of a cell line derived
from this mouse model showed increased expression of epithelial-mesenchymal transition genes
as well as increased matrigel invasion relative to a VM line.
ccRCC research is currently limited by the lack of a GEMM that accurately represents the
complete spectrum of phenotypes characteristic of human disease. As evidenced by the
publications described above, the various methods used to either delete tumor suppressors
and/or express oncogenes in distinct kidney lineages result in different propensities for ccRCC
development. Furthermore, the long latency of tumor formation in GEMMs currently available, as
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well as lack of metastatic spread typical of human ccRCC, poses challenges for researchers
studying the molecular mechanisms governing these events. In the meantime, identification of
subpopulations of established patient-derived cell lines having metastatic capacity (Vanharanta et
al., 2013) and incorporation of patient-derived xenografts will allow the field to investigate these
phenomena in greater detail. Additional GEMMs mimicking the initiation and progression of
ccRCC will ultimately be beneficial for the pre-clinical study of targeted therapy. A deeper
understanding of the genetic, epigenetic, and metabolic changes that synergize with VHL loss to
generate ccRCC, and the order in which they occur, will ultimately facilitate the development of
such tools.

1.2.c Metabolic reprogramming in ccRCC
Glucose utilization
Aerobic glycolysis, commonly known as the “Warburg effect,” is a hallmark of many
cancers regardless of cell-of-origin (Pavlova and Thompson, 2016), and this phenomenon is
amplified in VHL-deficient ccRCC due to HIF activation. A primary consequence of constitutive
HIF activation is decreased pyruvate entry into the TCA cycle and increased glycolytic flux
towards lactate due to the actions of pyruvate dehydrogenase kinase 1 (PDK1) and lactate
dehydrogenase (LDHA), respectively (Wettersten et al., 2017). It is believed that enhanced
glycolysis benefits tumors through several mechanisms, one being the generation of building
blocks for nucleotides, proteins, and lipids through pathways branching from glycolytic
intermediates (Ward and Thompson, 2012). The pentose phosphate pathway, beginning with
glucose-6-phosphate and generating NADPH and ribose 5-phosphate, is important for lipid and
nucleotide production. Additionally, NADPH produced from these reactions can be used to reduce
oxidized glutathione, helping to maintain antioxidant capacity in rapidly proliferating cells. The
hexosamine pathway, beginning with fructose 6-phosphate, is important for the generation of
precursors used in N-glycosylation of proteins. These modifications are important for the proper
folding of growth factor and nutrient receptors, which feeds back to regulate cellular metabolism
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more broadly (Wellen and Thompson, 2012). Although an inefficient means of ATP generation
relative to oxidative phosphorylation, aerobic glycolysis in cancer cells occurs at a rate much
higher than in non-proliferative cells (Liberti and Locasale, 2016). An equivalent rate of ATP
synthesis along with the additional generation of anabolic precursors and reducing equivalents is
a proposed explanation for why tumors rewire metabolism to promote the Warburg effect.
In addition to their canonical, catalytic functions, several reports demonstrate that certain
glucose metabolic enzymes exhibit dual functions through physical association with HIFs (Luo et
al., 2011), (Xie and Simon, 2017). The HIF-1α target gene pyruvate kinase (PKM) encodes
isoforms PKM1 and PKM2, of which PKM2 is a key regulator of glycolytic flux. The Semenza
group showed that in addition to its catalytic function, PKM2 can bind to HIF-1α as a co-activator
and enhance p300 recruitment and localization to hypoxia response elements (Luo et al., 2011).
Additionally, our group demonstrated that the gene encoding the gluconeogenic enzyme fructose1,6-bisphosphatase 1, FBP1, is uniformly silenced or deleted in ccRCC patients (Li et al., 2014).
Loss of FBP1 promotes ccRCC progression by two distinct mechanisms; first, by promoting
glycolytic flux in renal epithelial cells, and secondly, by dissociation with the HIF-α inhibitory
domain, facilitating constitutive HIF activity at the chromatin-level. Further research exploring the
relationship between HIFs and their cell type-specific transcriptional targets will provide insight
into the complex regulation of metabolism in ccRCC.

PI3K-Akt-mTOR pathway
The phosphoinositide 3-kinase (PI3K) signaling pathway is activated by copy number
variation or mutation of its positive effectors PIK3CA, MTOR, and negative regulators PTEN and
TSC1/2 in 28% of patients in ccRCC (Network, 2013; Turajlic et al., 2015). PI3K activation
activates Akt, also known as protein kinase B, by phosphorylation at the cell surface. One of the
major downstream targets of activated Akt is mTORC1, which increases anabolic pathways such
as protein, lipid, and nucleotide synthesis (Dibble and Manning, 2013). Inactivation of the
negative regulators of mTORC1, TSC1 and TSC2, has been associated with increased risk of
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ccRCC development, which presents at an earlier age than sporadic disease (Bjornsson et al.,
1996). Collectively, these effects render the pathway constitutively active even in the absence of
growth factors. The effects of altered glucose and amino acid metabolism on ccRCC
pathogenesis was comprehensively reviewed in 2017 (Wettersten et al., 2017), as such, we will
focus on reprogrammed lipid metabolism in the remainder of this section.

Lipid metabolism
As renal proximal tubule epithelial cells (RPTEC) transition into ccRCC, they undergo
dramatic rewiring of various metabolic pathways including lipid utilization, synthesis, and storage
(Figure 1.2). Healthy RPTEC are characterized by high rates of beta-oxidation to fuel their
primary role in ion exchange and secretion (Kang et al., 2015). Beta-oxidation is the process by
which lipids are broken down into acetyl-CoA, generating the reducing equivalents NADH and
FADH2 to produce ATP through oxidative phosphorylation. Compared to RPTEC, ccRCC have
reduced mitochondrial content and defective mitochondrial structure and activity (Meierhofer et
al., 2004), (Nilsson et al., 2015). At the gene expression level, transcriptional regulators of
mitochondrial homeostasis and oxidative phosphorylation are uniformly suppressed in ccRCC
relative to adjacent healthy kidney tissue (Tun et al., 2010). These adaptations are largely due to
constitutive HIF signaling, although additional factors regulating these pathways remain to be
explored. One study examined the relationship between HIF-α and PGC-1α, a peroxisome
proliferator-activated receptor gamma (PPARγ) transcriptional co-activator involved in the process
of mitochondrial biogenesis and respiration (Puigserver et al., 1998). VHL-deficient ccRCC cells
exhibit elevated levels of Dec1, a transcriptional repressor and HIF-α target gene, which blocks
expression of PGC-1α (LaGory et al., 2015). Ectopic expression of PGC-1α increased oxidative
stress and slowed tumor growth in a subcutaneous xenograft model. Furthermore, lower levels of
PPARGC1A (PGC-1α) mRNA were correlated with worse patient survival, and total mitochondrial
content was correlated inversely with tumor grade (Simonnet et al., 2002), consistent with its role
as a tumor suppressor in ccRCC.
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Transcriptional repression of carnitine palmitoyltransferase (CPT1A), the rate limiting
enzyme involved in fatty acid transport into the mitochondria for beta-oxidation, also occurs in
ccRCC via a HIF-α dependent mechanism (Du et al., 2017). A recent report found that pVHL
reconstitution in several ccRCC cell lines reduced lipid droplet (LD) accumulation in a CPT1A
dependent manner (i.e., knockdown of CPT1A in pVHL-reconstituted cells partially increased lipid
accumulation). Interestingly, pVHL status had no effect on lipid uptake rates, as measured
through the uptake of BODIPY, an unsaturated, fluorescently labeled fatty acid molecule. Ectopic
expression of CPT1A increased oxygen consumption rate, decreased LD abundance, and
decreased xenograft tumor growth. Clinically, CPT1A levels and activity are reduced in ccRCC
compared with healthy kidney tissue, and patients with reduced CPT1A expression have worse
prognosis.
Concomitant with decreased beta-oxidation in ccRCC tumors is increased lipid synthesis
and storage. Fatty acid synthesis occurs when cytosolic citrate is cleaved by the enzyme ATP
citrate lyase, or ACLY, to produce acetyl-CoA. Carboxylation of acetyl-CoA to malonyl-CoA by
acetyl-CoA carboxylase (ACC) generates the building blocks for long-chain fatty acid formation
which can go on to be desaturated and further modified to produce more complex lipid species.
Two key enzymes in this process are fatty acid synthase (FASN), which produces palmitic acid
(C16:0), and stearoyl-CoA desaturase 1 (SCD1), which primarily produces oleic acid (C18:1) from
the desaturation of stearic acid. In ccRCC, metabolism of glutamine-derived α-ketoglutarate to
citrate by reductive carboxylation fuels lipid synthesis rather than glucose-derived citrate
generated by oxidation (Gameiro et al., 2013; Metallo et al., 2012). In addition to increasing
anabolic lipid metabolism for the production of membranes needed during rapid cell proliferation,
new evidence suggests additional roles for de novo lipogenesis (DNL) and lipid uptake in
carcinogenesis. FASN levels correlate positively with tumor aggressiveness and poor survival in
ccRCC (Hakimi et al., 2016; Horiguchi et al., 2008), and genetic and pharmacologic inhibition of
SCD1 induces apoptosis in ccRCC cell lines both in vitro and in vivo (Von Roemeling et al.,
2013). Treatment with ACC inhibitor reduces total phospholipid and triglyceride content, as
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predicted, and also increases sensitivity to oxidative stress-induced cell death (Rysman et al.,
2010). Other work has demonstrated that lipid uptake protects against endoplasmic reticulum
(ER) stress in ccRCC and other cancers, particularly under hypoxia when cells cannot desaturate
fatty acids due to the inactivation of SCD1 (Kamphorst et al., 2013; Young et al., 2013).
The protective effect of LD accumulation in cancer cells is incompletely understood, although
recent studies suggest several mechanisms by which LDs can enhance tumorigenesis and cell
viability. LDs consist of a core of neutral lipids including triglyceride and cholesterol esters
surrounded by a monolayer of membrane from the endoplasmic reticulum and coat proteins
including the perilipin family (Walther and Farese Jr, 2012). Inhibition of the LD coat protein
perilipin 2 in ccRCC, a highly-expressed HIF-2α target gene, reduced neutral lipid accumulation,
tumor growth, and increased ER stress both in vitro and in vivo (Qiu et al., 2015). In glioblastoma
and breast cancer, it was recently demonstrated that lipid accumulation following hypoxiareoxygenation protects cells from reactive oxygen species (ROS)-induced cytotoxicity (Bensaad
et al., 2014). In another hypoxic microenvironment, the Drosophila neural stem cell niche, LDs
that form during oxidative stress reduce ROS levels and inhibit the oxidation of polyunsaturated
fatty acids (PUFA) (Bailey et al., 2015). When PUFA are stored in LDs rather than in membranes,
they are less vulnerable to peroxidation, which inhibits proliferation through damaging
macromolecules. In theory, these responses are even more critical to maintain in ccRCC, where
lipid accumulation is a defining molecular and morphological hallmark of disease. Taken together,
these results suggest pathways involving anabolic lipid metabolism could one day be targeted for
therapeutic benefit in ccRCC.
In a recently published lipidomic analysis of 49 patients (Saito et al., 2016), elevated levels of
ether-type phospholipids, cholesterol esters, and triacylglycerols were reported in ccRCC,
consistent with previously published metabolomic analyses (Gebhard et al., 1987; Hoffmann et
al., 2005; Yoshimura et al., 2012). These metabolic changes were also correlated with gene
expression levels of lipogenic genes. While it is clear that suppression of either HIF-1α or HIF-2α
markedly reduces LD formation in ccRCC (Du et al., 2017; Qiu et al., 2015; Sundelin et al., 2012),
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the target genes and mechanisms responsible for the clear cell phenotype have not been
completely defined. Additionally, the role of other lipogenic transcription factors such as sterol
regulatory element-binding protein 1 or 2 (SREBP1/2) and carbohydrate-responsive elementbinding protein (ChREBP) remain to be fully elucidated in ccRCC.

1.2.d Therapeutic strategies for ccRCC
Anti-angiogenics and mTOR inhibitors
Anti-angiogenic therapy targeting receptor tyrosine kinases (RTKs) such as vascular
endothelial growth factor receptor (sunitinib, sorafenib, etc) or VEGF ligand by monoclonal
antibody (bevacizumab) has traditionally been a first-line standard-of-care for ccRCC patients
(Ricketts et al., 2016) (a graphical representation of the therapies reviewed in this section is
presented in Figure 1.3). Although these agents are being investigated for several malignancies
including colorectal and lung cancers, anti-angiogenics are theoretically well-suited for the
treatment of ccRCC due to constitutive HIF activity and exceedingly high VEGF accumulation.
However, clinical trials indicate that at least as single-therapy, anti-angiogenic drugs are only
modestly effective for the treatment of metastatic ccRCC. In a randomized, double-blind trial of
bevacizumab, the probability of being progression-free after eight months was significantly
extended by 30% (high-dose), 14% (low-dose), and 5% (placebo) (Yang et al., 2003). However,
there was no significant difference in overall survival between placebo, low, or high-dose
bevacizumab. A phase III study of sunitinib in patients with high risk of tumor recurrence after
nephrectomy revealed that 64.9% of patients were disease-free at three years after adjuvant
treatment with sunitinib compared with 59.5% in the placebo group (Ravaud et al., 2016). At five
years, the proportions fell to 59.3% (sunitinib) and 51.3% (placebo). Side effects from sunitinib
treatment included diarrhea, hypertension, fatigue, and nausea.
Rapamycin analogs, or rapalogs (everolimus, temsirolimus), are used for the treatment of
advanced ccRCC after patients have been treated with a RTK inhibitor. A phase III study in
patients whose disease progressed after receiving either RTK- or VEGF-targeted therapy found
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that everolimus was effective in prolonging progression-free survival compared with placebo
control (Motzer et al., 2008). Side effects from everolimus included hyperglycemia,
hyperlipidemia, and hypercholesterolemia due to effects on mTOR-regulated glucose and lipid
metabolism, as well as diarrhea and rash. Yet overall, the risk of severe effects was low and no
detrimental effects on health-related quality-of-life was observed in everolimus treated individuals
compared with placebo. The clinical trials reported above led to FDA approval for angiogenesis
and mTOR inhibitors nearly a decade ago, and current investigation has now shifted toward
targeted therapy of HIF-2α as well as immune checkpoint blocade.

Targeting HIF-2α
HIF-2α is the primary oncogenic driver of ccRCC progression downstream of VHL loss.
Pre-clinical work from several labs has examined the efficacy of a HIF-2α inhibitors utilizing a
panel of ccRCC cell lines in orthotopic xenograft assays as well as patient-derived xenografts
grown subcutaneously (Chen et al., 2016b; Cho et al., 2016; Wallace et al., 2016). PT2399 blocks
the interaction between HIF-2α and HIF-1β/ARNT by binding to a pocket within the PAS-B
domain of HIF-2α, thereby eliminating DNA binding. Importantly, PT2399 reduces HIF-2α target
gene expression without affecting HIF-1α targets (Cho et al., 2016). When tested alongside
sunitinib, PT2399 decreased tumorgraft growth by 60% across all samples tested compared with
40% for sunitinib treatment, without causing a reduction in body weight as seen with the latter
drug (Chen et al., 2016b). Resistance mechanisms were observed in tumors initially sensitive to
PT2399, which were characterized by increased tumor vascularity and VEGF production despite
dissociation between HIF-2α and ARNT. However, they took nearly double the amount of time to
develop as tumors treated with sunitinib. Based on these results, a derivative of PT2399, PT2385,
is currently being tested in clinical trials for ccRCC (Medicine, 2018).

Targeting glutaminase
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Since being reviewed by Wettersten, et al., two phase II clinical trials have been initiated to
examine the effect of CB-839, a small molecule inhibitor of glutaminase, along with either
cabozantinib, everolimus, or placebo, on patients with advanced or metastatic RCC (Tannir et al.,
2018). Additionally, a pre-clinical report on the role of glutamine addiction in ccRCC further
supports the possibility of therapeutically targeting this axis in kidney cancer (Aboud et al., 2017).
Aboud, et al. demonstrate that ccRCC tumors grown orthotopically show increased uptake of
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(2S,4R)4-fluoroglutamine relative to adjacent healthy kidney tissue and are sensitive to
glutaminase inhibition by CB-839. These results suggest that PET imaging could be useful to
identify ccRCC patients likely to respond to glutaminase inhibition clinically.

Immunotherapy
Immune checkpoint blockade represents a promising strategy for the treatment of many
cancer subtypes including ccRCC. Such therapies remove the “brakes” from a patient’s immune
system, allowing T-cells to recognize and destroy cancer cells. While ccRCC does not harbor as
many somatic mutations per megabase as melanoma or non-small cell lung cancer, which
creates a higher neo-antigen load and is thought to predict response to immunotherapy, positive
immune responses can be achieved in a subset of patients (De Velasco et al., 2016; Schumacher
and Schreiber, 2015). One method of achieving this effect is to antagonize programmed cell
death-1 receptor (PD-1), which is found on activated T-cells and interacts with PD-L1 or PD-L2 on
tumor cells. This interaction normally allows tumor cells to evade the immune response, but when
inhibited restores antitumor immunity (Parikh and Lara, 2017). Clinical work comparing
nivolumab, a monoclonal antibody targeting PD-1, to everolimus, found that nivolumab extended
median survival to 25 months compared with 19.6 months for everolimus treatment in patients
with advanced ccRCC (Motzer et al., 2015). However, durable effects were only seen in 20-25%
of patients (De Velasco et al., 2016). Current investigations across cancer subtypes are geared
toward defining mechanisms that underlie positive and lasting responses to immune checkpoint
blockade. A recent study identified signatures of response to checkpoint therapies in ccRCC
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(Miao et al., 2018). Through whole exome sequencing of 35 tumors of patients with metastatic
ccRCC, it was determined that biallelic PBRM1 loss was associated with significantly longer
overall survival than patients with PBRM1 intact. It was hypothesized that PBRM1 loss-of-function
and subsequent alterations in SWI/SNF signaling networks may underlie this effect. It is the hope
that through these analyses, specific patient populations can be identified which would respond
best to immunotherapy based on the genetic and mutational landscape of their tumors.

1.3 Introduction to bladder urothelial carcinoma (UC)
th

Bladder urothelial carcinoma (UC) is the 4 most prevalent form of cancer diagnosed in
men in the United States, and is most commonly detected in patients over the age of 65. While
men have a 3 to 4-fold higher risk of bladder cancer incidence compared to women, women
typically are diagnosed at later stages and have a poorer prognosis (Berdik, 2017). The majority
of bladder cancers are derived from an epithelial layer known as the urothelium, or transitional
epithelium, which comprises the innermost lining of the bladder, ureters, and renal pelvis. Bladder
cancers arising from non-urothelial layers (i.e., sarcomas, squamous and small-cell carcinomas,
and adenocarcinomas) only account for 10% of all cases	
  (Sanli et al., 2017).
Top risk factors for UC include smoking (linked with 65% of cases in men and 30% in
women) and occupational exposure to carcinogens such as paint, rubber, petroleum products,
and dyes (Berdik, 2017), although occupational carcinogen exposure only accounts for 8% of
total cases worldwide (Purdue et al., 2015). Genetic background likely plays a large role in
disease susceptibility, although predispositions to UC development have been less studied until
recently. One study found that women with a history of smoking and either null mutations in the
N-acetyltransferase carcinogen-detoxification gene GSTM1 or polymorphisms in NAT2 (resulting
in “slow-acetylator” phenotype) are at increased risk of developing UC compared to smoking
women with wildtype gene function (García-Closas et al., 2005). Genome wide association
studies have implicated polymorphisms in the urea transporter gene SLC14A1 to UC
development, which modulates concentrations of carcinogens in the urine (Rafnar et al., 2011),
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as well as variants near 8q24.21. These polymorphisms map to a region near MYC which have
also been identified in GWAS of colorectal, breast, and pancreatic cancers (Rothman et al.,
2010).

Clinical stratification, disease subtypes and biomarkers
Clinically, UC is stratified into two types of disease: non-muscle-invasive bladder cancer
(NIMBC) and muscle-invasive bladder cancer (MIBC). NIMBC is the most frequently diagnosed
form of UC, accounting for 75% of cases each year in the United States. NIMBC represents
Stage 0 (T0) papillary tumors as well as Stage I carcinoma in situ (CIS), which is more aggressive
and likely to spread. Twenty-five percent of patients are initially diagnosed with MIBC, tumors
which have invaded through the lamina propria and into the outer muscle and fat layers of the
bladder (Stage II-IV) (Choi et al., 2014b). The most frequent sites of UC metastasis include lymph
nodes (69% of patients), bone (47% of patients), and lung (37% of patients) (Shinagare et al.,
2011).
Over the past three decades, the percentage of patients surviving 5 years after diagnosis
has been unchanged, compared to improvements seen in prostate, kidney, and breast cancer
survival rates (Berdik, 2017). This is largely due to limited targeted therapeutic options and a
standard of care regimen which has been constant during the same time period (discussed
below). In order to identify common transcriptional signatures that may provide insight into
rational therapeutic options, three different groups have independently classified MIBC tumors
into subcategories based on RNA-sequencing. Specific demarcations are as follows: University of
North Carolina (UNC): basal and luminal	
  (Damrauer et al., 2014). MD Anderson Cancer Center
(MDA): Basal, p53-like, luminal (Choi et al., 2014b). TCGA: Clusters I and II (enriched with breast
cancer luminal markers), Clusters III and IV (enriched with breast cancer basal markers)
(Network, 2014). Basal tumors are characterized by squamous histology and are generally more
aggressive, yet also highly sensitive to cisplatin-based combinatorial chemotherapy. Luminal
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tumors are characterized by papillary histology and are slower growing, but also more chemoresistant (Choi et al., 2014b).
Major biomarkers of the luminal subtype of UC include PPARγ, estrogen receptor 1
(ESR1), receptor tyrosine kinase ERBB2 (also known as HER2/neu), and fibroblast growth factor
receptor 3 (FGFR3). The differentiation status of luminal MIBC tumors can also be assessed by
the presence of uroplakins, proteins which form plaques on the apical surface of the urothelium to
act as a permeability barrier	
  (Wu et al., 2009). Biomarkers of the basal subtype include TP63
(p63), STAT3, HIF-1α, and epidermal growth factor receptor (EGFR) (Damrauer et al., 2014).
Keratin proteins (KRT5, KRT6, and KRT14) are enriched in basal MIBCs as well as a lethal
squamous cell carcinoma subtype, and are important for the invasive properties of these cancers
(Sjödahl et al., 2012).

Mouse models of UC
As there is no uniform molecular driver of UC pathogenesis as in other urinary system
cancers (i.e., ccRCC, loss of the tumor suppressor gene VHL), generation of MIBC in mice
requires the deletion of multiple tumor suppressor genes such as Trp53, Rb1, or Pten in the
urothelium. A commonly used model for the generation of UC in mice is Upk2-Cre, where the
uroplakin 2 gene promoter drives the expression of Cre-recombinase in urothelial cells (de la
Peña et al., 2011). Notably, Upk2-mediated expression of a dominant-negative p53 mutant alone
in the urothelium is insufficient to generate UC, as these mice do not develop urothelial
hyperplasia until at least 10 months of age (Gao et al., 2004). This result is surprising given that
nearly 50% of MIBC harbor inactivating mutations in TP53 (Hurst et al., 2018). In the
combinatorial models, CIS lesions develop first, followed by high-grade MIBC with features
common to human disease including ERBB2 and PI3K pathway upregulation (Gao et al., 2004;
Puzio-Kuter et al., 2009; Zhang et al., 1999).
Carcinogen-induced UC typically involves oral administration of N-butyl-N-(4hydroxybutyl) nitrosamine (BBN) in rodents, which also generates tumors with morphological
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features reminiscent of human UC (FUKUSHIMA et al., 1976; Grubbs et al., 1977). However,
latency and incomplete incidence of tumors are two limitations of this model. For example,
administration of 150 mg BBN by oral gavage twice weekly for 8 weeks will result in UC in 48% of
rats, detectable 10 months after administration (Lubet et al., 2008). In C57BL/6 mice, continuous
dosage of 35 mg/kg/day BBN in the drinking water results in UC after 190 days and males and
253 days in females, with metastatic spread detectable in 13 out of 100 mice. Interestingly, this
sex difference in tumor onset can be abolished either through castration of males or treating
females with testosterone	
  (Bertram and Craig, 1972). While the BBN model may be more
comparable to environmental carcinogen exposure affecting human disease, the latency of tumor
initiation and low incidence of metastasis are important considerations to performing pre-clinical
studies using this reagent.

1.3.a Therapeutic strategies for UC
NIMBC is treated by a procedure called transurethral resection of bladder tumor
(TURBT), which can also be followed by adjuvant intravesical therapies. The most common
intravesical therapy is the delivery of a substrain of Mycobacterium bovis named Bacillus
Calmette-Guerin (BCG), which is related to tuberculosis and used to stimulate an immune
reaction within the bladder (Brandau and Suttmann, 2007). Alternatively, chemotherapy such as
mitomycin, gemcitabine, or valrubicin can be delivered directly to the bladder via a catheter, yet
BCG immunotherapy is superior to intravesical chemotherapy in preventing bladder cancer
recurrence (Böhle et al., 2003).
Treatment of MIBC or recurrent NIMBC is much more invasive, typically involving radical
cystectomy. This “gold-standard” intervention not only includes removal of the entire bladder, but
other reproductive organs such as the prostate and seminal vesicles for men and the uterus,
ovaries, and part of the vagina for women (Sanli et al., 2017). Radical cystectomy is followed by
construction of a “neobladder” using a portion of the intestines, or the creation of a urostomy to
divert urine to an external bag. The 10-year recurrence-free survival following radical cystectomy
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is 86% for T0 tumors and 76% for T1-T3, but drops to 34% when disease has metastasized to
lymph nodes	
  (Stein et al., 2001). While intravenous delivery of neoadjuvant chemotherapy (prior
to cystectomy) has only been associated with small increases in disease-free survival at 5 years
(~5%), adjuvant chemotherapy cocktails including methotrexate, vinblastine, adriamycin, cisplatin
(MVAC) or gemcitabine with cisplatin produces a pathological complete response in 30-40% of
patients (Sternberg et al., 2013). In the coming decades, the combination of immunotherapy
and/or possible targeted therapies based on “druggable” biomarkers associated with basal or
luminal subcategories of MIBC will hopefully reduce the need for invasive surgical procedures
and improve UC survival.

1.4 Main hypothesis and objectives
The focus of my thesis research has been elucidating the role of PPARγ in ccRCC and
UC. Since PPARγ is expressed in a subset of both ccRCC and UC tumors at levels higher than
their adjacent epithelium/cell-of-origin (Collet et al., 2011; Network, 2014), our general hypothesis
was that PPARγ has pro-oncogenic functions in both tumor types. The questions that have
guided these investigations have been: 1) How does PPARγ-RXR genomic occupancy differ
between lineages? 2) Does PPARγ primarily regulate genes involved in lipid and glucose
metabolism in these cancer subtypes, or are there unique targets that contribute to the cell-type
specific functions of this nuclear receptor? 3) Does inhibiting PPARγ activity, either
pharmacologically or genetically, affect tumor growth of ccRCC and UC? If so, what are the
molecular mechanisms responsible for this dependency? To answer these questions, I used
multiple human cell lines derived from each tumor type in various in vitro and in vivo assays of
tumor progression. I also employed genome-wide techniques including ChIP-seq and RNA-seq to
investigate PPARγ-RXR genomic occupancy and its effects on gene expression in these cancer
models. In Chapters 2 and 3, I explore these questions in ccRCC and UC, respectively. In
Chapter 4, I summarize the findings of my thesis research and address several remaining
questions related to this work.
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Figure 1.1: Regulation of hypoxia-inducible factor (HIF) signaling by the von Hippel-Lindau
(VHL) tumor suppressor
Under oxygen-replete conditions, HIF-α subunits are hydroxylated by prolyl hydroxylases (PHDs) and
then ubiquitinated by an E3-ubiquitin ligase complex containing pVHL, tagging them for proteasomal
degradation. In hypoxia, or when VHL is inactivated (such as in ccRCC), HIF-α subunits escape
degradation, translocate to the nucleus, and heterodimerize with HIF-1β (ARNT). HIFs generally
promote a transcriptional program favoring increased angiogenesis, glycolysis, and metastatic
capabilities of ccRCC tumors. HRE = hypoxia response element.
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Figure 1.2: Comparison of the metabolic state of renal epithelium and clear cell renal cell
carcinoma (ccRCC)
Renal epithelial cells (of the proximal tubule, a proposed cell-of-origin of ccRCC) are characterized by
high levels of glucose and fatty acid oxidation to serve their energetic needs. As these cells transition
into ccRCC, they begin to store triglyceride and cholesterol ester in cytoplasmic lipid droplets.
Furthermore, ccRCC have low levels of fatty acid oxidation and compromised mitochondrial
architecture relative to healthy renal epithelium. Nuc = nucleus. Mito = mitochondria. LD = lipid droplet.
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Figure 1.3: Select pharmacological approaches for the treatment of metastatic ccRCC
Current and future therapeutic strategies for ccRCC include inhibition (denoted by red boxes) of mTOR
signaling, angiogenesis, HIF-2α signaling, and immune checkpoint blockade. RTKi = receptor tyrosine
kinase inhibitors. Rapalogs = rapamycin analogs. PD-1i = PD-1 inhibitor. PD-L1i = PD-L1 inhibitor.
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Chapter 2: PPARγ is dispensable for clear cell renal cell carcinoma progression

This chapter has been adapted with modifications from: Sanchez, DJ, Steger, DJ, Skuli, N,
Bansal, A, Simon, MC. PPARγ is dispensable for clear cell renal cell carcinoma progression. Mol
Metab. 2018 Aug;14:139-149. doi: 10.1016/j.molmet.2018.05.013.
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2.1 Abstract
Clear cell renal cell carcinoma (ccRCC) is a subtype of kidney cancer defined by robust
lipid accumulation, which prior studies have indicated plays an important role in tumor
progression. We hypothesized that the peroxisome proliferator-activated receptor gamma
(PPARγ), detected in both ccRCC tumors and cell lines, promotes lipid storage in ccRCC and
contributes to tumorigenesis in this setting. PPARγ transcriptionally regulates a number of genes
involved in lipid and glucose metabolism in adipocytes, yet its role in ccRCC has not been
described. The objective of this study was to elucidate endogenous PPARγ function in ccRCC
cells. Using chromatin immunoprecipitation followed by deep sequencing (ChIP-seq), we found
that PPARγ and its heterodimer RXR occupy the canonical DR1 PPAR binding motif at
approximately 1000 locations throughout the genome that can be subdivided into adipose-shared
and ccRCC-specific sites. CRISPR-Cas9 mediated, loss-of-function studies determined that
PPARγ is dispensable for viability, proliferation, and migration of ccRCC cells in vitro and in vivo.
Also, surprisingly, PPARγ deletion had little effect on the robust lipid accumulation that typifies the
“clear cell” phenotype of kidney cancer. Our results suggest that PPARγ plays neither a tumor
suppressive nor oncogenic role in advanced ccRCC, and thus single-agent therapeutics targeting
PPARγ are unlikely to be effective for the treatment of this disease. The unique cistrome of
PPARγ in ccRCC cells demonstrates the importance of cell type in determining the functions of
PPARγ.
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2.2 Introduction
th

Kidney cancer is the 8 most prevalent form of cancer diagnosed each year in the United
States, with approximately 64,000 new diagnoses and 14,400 deaths annually (Institute, 2018).
While localized disease can be treated by surgical resection, 30% of patients initially present in
the clinic with metastatic disease, which carries a poor prognosis due to limited efficacy of current
standard-of-care therapies (Rydzanicz et al., 2013). As such, a significant clinical need remains
for therapeutics targeting unique genetic and metabolic vulnerabilities within this tumor type.
Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, is
defined by constitutive hypoxia-inducible factor signaling as well as widespread changes in
cellular metabolism of glucose, amino acids, and lipids (Wettersten et al., 2017). Phenotypically,
ccRCC is characterized by robust intracellular lipid and glycogen accumulation, resulting in
“cleared” cytoplasm when prepared for common histologic analyses. Rather than simply reflecting
a byproduct of increased anabolic metabolism, recent studies suggest that maintaining the
integrity of neutral lipid droplets as well as abundant lipid uptake is critical to maintain ccRCC cell
viability (Qiu et al., 2015), particularly when oxygen is limiting in the tumor microenvironment
(Young et al., 2013). However, factors imparting a lipogenic quality to ccRCC tumors remain to be
fully elucidated.
The peroxisome proliferator-activated receptor gamma (PPARγ) along with its
heterodimeric DNA-binding partner retinoid X receptor (RXR) promote the transcription of genes
broadly important for lipid, glucose, and hormone metabolism, most notably in the context of
adipose tissue (Ahmadian et al., 2013). PPARγ, the master regulator of adipogenesis, is both
necessary and sufficient for this process in vitro and in vivo (Tontonoz et al., 1994; Wang et al.,
2013). Additionally, in non-adipose contexts including ischemic, diseased cardiomyocytes
(Krishnan et al., 2009) and macrophages (Chawla et al., 2001a), PPARγ contributes to the
regulation of genes involved in lipid metabolism. In a mouse model of high fat diet (HFD)-induced
hepatosteatosis, PPARγ protein expression is elevated in the livers of mice fed HFD relative to
controls (Morán-Salvador et al., 2011), although the absolute level remains far below those
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observed in adipose tissues. Interestingly, conditional deletion of Pparg within hepatocytes
abrogated liver steatosis, suggesting a link between PPARγ and lipid uptake, synthesis, and/or
storage in this model.
Previous reports indicate that PPARγ is functionally expressed (Collet et al., 2011) in
ccRCC and that increased PPARγ abundance correlates with reduced patient survival (Zhu et al.,
2015), suggesting a possible oncogenic function. In vitro studies investigating the role of PPARγ
in ccRCC and other cancers have largely employed natural and synthetic activating ligands
including the insulin-sensitizing thiazolidinediones, yet many used super-physiologic
concentrations which can cause off-target effects and confound interpretation of results (Fujita et
al., 2011; Shiau et al., 2005). In this study, our goal was to investigate endogenous PPARγ
function through ChIP-seq and a number of in vitro and in vivo assays of tumor progression using
loss-of-function models in established ccRCC cell lines.
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2.3 Materials and Methods
Primary Patient Samples and Gene Expression Data
Matched tumor/normal samples were obtained from the Cooperative Human Tissue
Network (CHTN). Tumors were homogenized in TRIzol (see quantitative real-time PCR) or whole
cell elution buffer (see Western blot) and analyzed for PPARG mRNA and protein expression.
Gumz, et al. microarray dataset was downloaded from Oncomine. RNA-seq data for 480 ccRCC
and 69 normal kidney samples were downloaded from TCGA on April 2, 2013. Differential gene
expression analysis of tumor and normal samples was performed using DeSeq (Bioconductor
Version 2.12). TCGA mutation and copy number data for 418 sequenced patients/cases were
downloaded from cBioPortal for Cancer Genomics (Network, 2013).

Cell Culture, Plasmids, Lentiviral Production, and Viral Transduction
Human ccRCC cell lines (RCC10, UMRC2, Caki2, 786-O, A498, 769-P) were obtained
from the American Type Culture Collection (ATCC) and were cultured in DMEM (ThermoFisher
Scientific, cat. 11965092) supplemented with 10% FBS (Gemini Bio-Products, cat. 900-108).
Immortalized renal epithelial cells (HK2) obtained from ATCC and cultured in Keratinocyte Serum
Free Media with appropriate supplements (ThermoFisher Scientific, cat. 17005042). Human
single-guide RNAs (sgRNA) targeting PPARG #1 (ctccgtggatctctccgtaa) and #3
(cattacgaagacattccatt) along with control gRNA targeting mouse Rosa26 locus
(aagatgggcgggagtcttct) were cloned into LentiCRISPRv2 plasmid (Sanjana et al., 2014). Mature
antisense human PPARG shRNA #3 sequence (clone ID: TRCN0000001673) along with
scrambled (SCR) control were cloned into a doxycycline-inducible pLKO lentiviral plasmid
(AddGene, cat. 21915, (Wiederschain et al., 2009)). Lentivirus was prepared by co-transfection of
293T cells with shRNA or CRISPR plasmid of interest along with packaging plasmids pVSVg
(AddGene, cat. 8454), psPAX2 (AddGene, cat. 12260) and Fugene6 transfection reagent
(Promega). Lentivirus-containing media was collected from plates at 24 and 48 hours posttransfection, filtered using a 0.45 µm filter, and stored at -80°C. For viral transduction, cells were
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incubated with lentivirus-containing medium and 8 µg/mL polybrene for 24 hours. Cells were
allowed to recover for another 24 hours before selection with puromycin. All experiments were
performed with cells that survived puromycin selection and displayed knockdown/knockout of
PPARG as assayed by Western blot.

Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (ThermoFisher Scientific, cat. 15596026)
and RNeasy mini kit (Qiagen, cat. 74104). Reverse transcription was performed using HighCapacity RNA-to-cDNA (Applied Biosystems, cat. 4387406). qRT-PCR was performed using
ViiA7 Real-Time PCR system (Applied Biosystems) with TaqMan master mix (Life Technologies).
TaqMan probes were used to quantitate expression of PPARG (cat. Hs01115513_m1), FABP4
(cat. Hs01086177_m1), CD36 (cat. Hs01567185_m1) SLC38A4 (Hs00394339_m1), and
normalized to housekeeping genes HPRT1 (cat. Hs02800695_m1) and TBP (Hs00427620_m1).

Western Blot
Cells were washed with PBS prior to lysis in whole cell elution buffer (150 mM NaCl, 10
mM Tris pH 7.6, 0.1% SDS, and 5 mM EDTA) containing Roche ULTRA protease inhibitor
cocktail (cat. 05892791001). Proteins were resolved by SDS-PAGE, transferred to nitrocellulose
membranes, and immunoblotting was performed by incubating with primary antibodies overnight
at 4°C. The next day, membranes were incubated with secondary antibody and Western
Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (PerkinElmer, cat.
NEL103E001EA) was used to visualize proteins. All primary antibodies were diluted of 1:1000 in
5% w/v nonfat milk (except GAPDH, 1:10,000), and secondary antibodies were diluted 1:2000 in
5% w/v nonfat milk. PPARγ (cat. 2435), FASN (cat. 3180), GAPDH (cat. 2118), anti-Rabbit IgG,
HRP-linked (cat. 7074), anti-Mouse IgG, HRP-linked (cat. 7076) were purchased from Cell
Signaling Technology. SREBP1 (cat. 13551) was purchased from Santa Cruz Biotechnology.
SCD (cat. 19862) was purchased from Abcam.
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Chromatin Immunoprecipitation (ChIP) and ChIP-seq
ChIP was performed with whole cell extracts isolated from UMRC2 PPARγ WT and
PPARγ KD cell lines using 10 µg PPARγ (Santa Cruz, cat. sc-7196) or 10 µg RXRα/β/γ (Santa
Cruz, cat. sc-774) antibodies for immunoprecipitation (IP). Briefly, confluent 10 cm dishes of cells
were prepared by crosslinking with 1% formaldehyde for 15 minutes at room temperature, and
quenched with 125 mM glycine for 5 min at room temperature. Cells were harvested by scraping
and pellets were resuspended in 200 µl SDS lysis buffer (50 mM HEPES/NaOH pH 7.5, 1% SDS,
10 mM EDTA, 1 mM PMSF, and Roche ULTRA protease inhibitor cocktail (cat. 05892791001))
on ice for 10 minutes. Sonication was performed using Bioruptor Pico (Diagenode, cat.
B01060010) on high setting for 30 seconds, followed by centrifugation of lysates to remove
cellular debris. 100 µl of sheared chromatin from each tube was then diluted 10X, with 5% saved
as Input DNA and the rest prepared for either PPARγ or RXR IP.
PPARγ WT, PPARγ KD, RXR, and Input libraries were prepared in duplicate from two
independent biological replicates. For ChIP-seq, sequencing data was mapped to the human
genome (GRCh38) using STAR (Dobin et al., 2013) with parameters appropriate for ungapped
alignments. Peaks were called for each sample with input samples as background by HOMER
(Heinz et al., 2010). HOMER was also used for differential peak calling (PPARγ WT vs. KD and
RXR WT vs. KD) and to annotate peaks to proximal genes as described in Ensembl v85
(http://www.ensembl.org/index.html). For bioinformatics analyses displayed in Figure 2C - 2F,
1031 “high-confidence sites” were defined by the following criteria: peak score ≥ 10 (≥ 1 read per
million), fold change (PPARγ WT vs. KD) ≥ 2, RXR peak called with strict overlap. Motif
enrichment analysis was performed on this filtered peak list (1031 peaks) using HOMER against
the standard list of known motifs; de novo motif discovery included consideration of lengths
8,10,12,15,18 bp.

Annexin V-PI Apoptosis Assay
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30,000 cells of each cell line were plated in triplicate on 6-well plates. Four days later,
cells were prepared using the FITC–Annexin V, PI Kit (BD Biosciences, cat. 556547) according to
the manufacturer’s instructions. Flow cytometry was performed using the BD Accuri C6
instrument, with viable cells represented as the double-negative population.

2D and 3D Proliferation Assays
For 2D proliferation assays, 30,000 cells of each cell line were plated in triplicate on 6well plates. The following day (represented as Day 0), cells were trypsinized and counted using
the Countess Automated Cell Counter (Invitrogen, cat. C10281), as per the manufacturer's
instructions with Trypan blue. Cells were then counted again at the indicated timepoints. For 3D
proliferation assays, 3,000 cells of each cell line were plated in 24 wells of a Corning Costar 96well Ultra-low attachment round bottom plate (Sigma-Aldrich, cat. CLS7007) (Vinci et al., 2012).
Cells were mixed with Matrigel (BD Biosciences, cat. 356234) at a final concentration of 2.5%,
and plates were centrifuged at 1800 rpm for 10 minutes to form spheroids. The following day
(represented as Day 0), spheroids were imaged using the Invitrogen EVOS FL Auto Cell Imaging
System, and were imaged again at the indicated timepoints over the course of two weeks.
Spheroid volume was calculated using a previously published ImageJ macro (Ivanov et al., 2014).

Subcutaneous Xenograft
Experiments were approved by the Animal Care and Use Committee at the University of
Pennsylvania. Six female NIH-III nude mice (Charles River Laboratories, 4-6 weeks old) were
6

injected in each flank with 5x10 UMRC2 control or PPARG KO cells. Cells were resuspended in
ice-cold PBS and were mixed 1:1 with Matrigel (BD Biosciences, cat. 356234) in a final volume of
200 µL per injection. Tumor volumes were recorded at the indicated timepoints using caliper
2

measurements, calculated by the formula V=(π/6)(L)(W ), where L was the longer measurement
and W was the shorter measurement. At Day 75 post-injection, mice were sacrificed by CO2
inhalation and tumors were dissected for further analyses.
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Immunohistochemistry
Xenograft tumors were dehydrated, embedded in paraffin, and sectioned for staining.
Immunohistochemistry was performed as previously described (Qiu et al., 2015) using 1:200
PPARγ (Cell Signaling Technology, cat. 2435), 1:100 Ki67 (Abcam, cat. Ab15580), and 1:400
Cleaved Caspase-3 (Cell Signaling Technology, cat. 9661).

Oil Red O Staining
Oil Red O powder (350 mg) was dissolved in 100 mL 100% isopropanol as a stock
solution. Working solutions were prepared by mixing 60% stock with 40% H2O, vortexing, and
resting for 30 minutes at room temperature before filtering through a 0.2 µm filter. Cells were
washed twice in PBS, fixed in 4% paraformaldehyde for 15 minutes, and then incubated with the
Oil Red O working solution for 30 minutes at room temperature. Three more PBS washes were
performed before cells were counterstained with hematoxylin and coverslipped for imaging.

BODIPY (493/503) Staining
50,000 cells of each cell line were plated in triplicate on 6-well plates. Three days later,
live cells were washed twice in PBS and incubated in 2 µg/mL BODIPY 493/503 (Life
Technologies, cat. D3922) in PBS for 15 minutes at 37°C. After staining and trypsinization, cells
were washed twice in PBS and fixed in 2% paraformaldehyde for 15 minutes in the dark. Fixed
cells were washed and resuspended in PBS, passed through a cell strainer, and flow cytometry
was performed on a BD Accuri C6 instrument under FL-1.

Triglyceride Measurement
Xenograft tumors were homogenized in complete lysis buffer (50 mM Tris pH 7.4, 140
mM NaCl, 0.1% Triton X-100, 1 mM PMSF) containing Roche ULTRA protease inhibitor cocktail
(cat. 05892791001) using a Tissue-Tearor (BioSpec Products, cat. 985370). Triglyceride content
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was measured using the LiquiColor Triglycerides kit (Stanbio Laboratory, cat. 2100) according to
the manufacturer’s instructions and data were normalized to weight of each sample.

In Vitro Migration (Scratch) Assay
UMRC2 and A498 control and PPARG KO cell lines were plated to reach confluence the
following day. Scratches were made on the plates using a pipette tip and immediately imaged
(represented as 0 hr). 16 hours later, the scratched wells were imaged once again. For both
timepoints, wound area was determined using ImageJ, and data are expressed as scratch area
remaining at 16 hr relative to 0 hr timepoint.

Soft Agar Colony Formation Assay
UMRC2 and A498 control and PPARG KO cell lines were plated at a density of
6,000 cells per well (in 6-well plates) in complete DMEM containing 0.3% agarose (low-melt 2hydroxyethylagarose, Sigma Aldrich A4018), onto underlays composed of DMEM containing
0.6% agarose. Additional media was added to the cultures once per week, and after three weeks
of growth the colonies were quantified.

Statistics
Statistical analyses were performed using GraphPad Prism version 7 software, using
unpaired t-test with Welch’s correction. Data are presented as mean ± SEM of at least three
independent experiments. Statistical significance was defined as *** (p < 0.001), ** (p < 0.01), * (p
< 0.05), n.s. = not significant.
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2.4 Results
2.4.a PPARγ expression in ccRCC patient samples and cell lines
A 43 megabase region of chromosome 3p harbors bona fide and putative tumor
suppressor genes in ccRCC (Peña-Llopis et al., 2013) including von Hippel-Lindau (VHL), the
most commonly mutated gene in ccRCC and initiating tumorigenic event (Mandriota et al., 2002).
Unlike tumor suppressor genes located in this region, such as VHL, SETD2, PBRM1, and BAP1,
PPARG is free from mutations which could render the protein non-functional or functional as a
dominant-negative factor, and retains wildtype sequence in 96% of ccRCC tumors (Figure 2.1A).
PPARG mRNA expression is elevated in early-stage ccRCC relative to matched healthy kidney
tissue (Figure 2.1B) (Gumz et al., 2007; Tun et al., 2010). The Cancer Genome Atlas (TCGA)
RNA-seq data stratified according to tumor stage confirmed a significant increase in PPARG
transcripts in stage I and II patients, with non-significant changes in stages III and IV relative to
normal kidney tissue (Figure 2.1C). To verify PPARG mRNA and protein expression in ccRCC,
we examined matched tumor/normal pairs by RT-qPCR and Western blot. PPARG mRNA
(Figure 2.1D) and protein (Figure 2.1E) abundances were variable between tumor/normal
samples, yet a subset of samples displayed elevated PPARγ expression relative to adjacent
healthy kidney tissue. PPARγ expression in the kidney is highest in medullary collecting ducts
(Guan et al., 2005; Guan et al., 1997) and is not expressed significantly in renal proximal tubule
epithelial cells (RPTEC), a proposed cell-of-origin for ccRCC (Chen et al., 2016a; Yoshida et al.,
1986). This may explain the heterogeneity observed across the kidney lysates sampled. We
further examined PPARγ expression in a panel of ccRCC cell lines relative to immortalized (HK2)
and purified primary (RPTEC) cells (Figure 2.1F-G), and found elevated mRNA and protein
abundance in ccRCC relative to control in 4 out of 6 lines tested.

2.4.b Genome-wide analysis of PPARγ-RXR binding in ccRCC
To understand the functional role of PPARγ in kidney cancer, we sought to characterize
the PPARγ-RXR cistrome in the context of ccRCC and determine the relatedness of genomic
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occupancy to that found in adipocytes. ChIP-qPCR interrogating a number of adipocyte sites
(Soccio et al., 2011) in the UMRC2 cell line revealed coordinated occupancy for PPARγ and its
heterodimeric binding partner RXR at PDK4 and PLIN1 (Figure 2.2A). To examine occupancy
across the entire genome, we performed chromatin immunoprecipitation followed by deep
sequencing (ChIP-seq) for PPARγ and RXR. We identified 1031 binding sites based on the
following criteria: peak score greater than or equal to 10, wildtype vs. knockdown fold change
greater than or equal to 2 (validation of PPARγ protein knockdown in Figure 2.3A), and RXR
peak called with strict overlap (Figure 2.2B). We validated PPARγ binding at eight of the top sites
called in our data set based on peak score using control and PPARG KO cells (Figure 2.4A-C,
Table 1). Additionally, we addressed the functionality of PPARγ binding in ccRCC cells through
an shRNA-resistant cDNA rescue experiment. Ectopic expression of PPARγ increased the
expression of SLC38A4, a gene with two PPARγ-RXR binding sites within 10 kb of the
transcriptional start site (Figure 2.4D). When cells were treated with shRNA targeting PPARG,
SLC38A4 expression was diminished, but not when cells also contained the resistant cDNA
(Figure 2.4E-F). These data suggest that SLC38A4 is a direct transcriptional target of PPARγ in
ccRCC and provide evidence that endogenous PPARγ activity regulates gene expression in our
cell culture models.
Through de novo motif analysis we found that the canonical nuclear receptor direct
repeat 1 (DR1) motif is most highly enriched under PPARγ-RXR bound DNA in ccRCC, present
at 60.3% of sites (Figure 2.2C). Other transcription factor motifs represented include RAR-related
orphan receptor alpha (RORA) at 17.3% of sites and the hepatocyte nuclear factors alpha
(HNF1A, 16.3% of sites) and gamma (HNF4G, 5.7% of sites). Interestingly, the C/EBP motif,
which is found at 91% of PPARγ-binding regions in adipocytes (Lefterova et al., 2008), is only
found at 4.6% of PPARγ-RXR-bound regions in ccRCC. Consistent with previously published
ChIP-seq data sets in tissues including adipocytes and macrophages (Lefterova et al., 2010)
(Schmidt et al., 2011), PPARγ-RXR is bound most frequently at intergenic (37.2%) and intronic
(47.1%) regions of the genome in ccRCC, rather than at promoter-transcriptional start sites
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(10.4%) (Figure 2.2D). We then annotated peaks to the nearest gene and performed gene
ontology analysis to determine putative PPARγ-regulated pathways in ccRCC. Annotation of
“adipose-shared” genes include “metabolism of lipids and lipoproteins”, “organic acid metabolic
process”, and “lipid localization” (Figure 2.2E), whereas “ccRCC-specific” genes belonged to
cellular processes broadly important in cancer cell biology, including signal transduction and
regulation of cell shape and size (Figure 2.2F).

2.4.c PPARγ is dispensable for ccRCC viability and proliferation in vitro
As PPARγ was shown to bind near genes associated with regulation of protein
serine/threonine kinase activity and G2/M transition of mitotic cell cycle in ccRCC (Figure 2.2F),
we hypothesized that its loss would affect cell growth over time. Upon confirming effective
knockout of PPARγ using CRISPR-Cas9 (Figure 2.3B, Figure 2.5A), we subjected UMRC2 and
A498 ccRCC cell lines to a variety of in vitro assays to determine the functional consequence of
PPARγ loss. PPARG KO did not affect the viability (Figure 2.5B-C) or proliferation rate (Figure
2.5D-E) of either cell line when cells were grown in replete conditions (21% O2, 25 mM glucose
and 10% FBS). Since oxygen and nutrient limitation can profoundly influence cancer cell growth,
we embedded control and PPARG KO cells in Matrigel and allowed tumor spheroids to proliferate
over the course of two weeks. PPARG KO did not affect spheroid volume during the assay
(Figure 2.5F-H).
Additional “ccRCC-specific” PPARγ bound genes included those involved in “regulation of
cell shape” and “regulation of locomotion”, which we hypothesized could affect migratory
capacity. We plated UMRC2 and A498 cells to confluency and performed an in vitro scratch
assay to measure migration over the course of 16 hours, a timepoint chosen based on the nearly
complete recovery of the wound prior to the doubling time. We found no significant difference in
the percentage of wound healing that occurred between control and PPARG KO cells (Figure
2.6A-B). We also found that PPARγ depletion only modestly affected anchorage-independent
growth of UMRC2 and A498 ccRCC cells (Figure 2.6C-D).
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2.4d PPARγ is dispensable for ccRCC xenograft tumor growth in vivo
To assess the function of PPARγ in ccRCC tumor growth in vivo, we implanted UMRC2
control and PPARG KO cells subcutaneously into opposing flanks of NIH-III nude mice. Analysis
of tumor volume (Figure 2.7A) over the course of the experiment and tumor weights at day 75
post-injection (Figure 2.7B) revealed no significant difference in the growth of PPARG KO tumors
relative to control. Additionally, control and PPARG KO tumors were sectioned and
immunohistochemistry was performed for markers of proliferation (Ki67) and apoptosis (cleaved
caspase-3), as well as to confirm PPARγ loss over the duration of the assay (Figure 2.7C).
Quantitation of these markers revealed no significant difference between control and PPARG KO
tumors, suggesting that PPARγ is dispensable for ccRCC cell growth in vivo (Figure 2.7D-E).

2.4.e Lipid storage and triglyceride synthesis occur independently of PPARγ in ccRCC
As PPARγ is responsible for promoting lipid uptake and storage in adipocytes, and is
bound near lipid metabolism related genes in our model (Figure 2.2E), we hypothesized that its
loss in ccRCC would reduce neutral lipid content. Surprisingly, we found that loss of PPARγ did
not affect lipid accumulation in either ccRCC cell line tested in vitro by Oil Red O (Figure 2.8A) or
BODIPY 493/503 (Figure 2.8B) staining. In agreement with this, expression of a number of
proteins involved in de novo lipogenesis that are reduced following hepatocyte-specific deletion of
PPARγ (Morán-Salvador et al., 2011), including sterol regulatory element-binding protein 1
(SREBP1), fatty acid synthase (FASN), and stearoyl-CoA desaturase 1 (SCD), did not change
substantially following PPARγ loss in our models (Figure 2.8C). Additionally, we measured
triglyceride levels in control and PPARG KO xenograft tumors to determine whether exposure to
oxygen and nutrient depletion in vivo would affect the ability of the cells to store triglyceride.
Consistent with our in vitro results, we found no significant difference in triglyceride content
between control and PPARG KO tumors (Figure 2.8D). These data indicate that PPARγ is
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dispensable for the “clear cell” phenotype of renal cancer with regard to triglyceride synthesis and
storage.

2.5 Discussion
“Druggability” of nuclear receptors via small molecule agonists or antagonists make them
appealing therapeutic targets to treat diseases like diabetes and cancer. Across various tumor
types, studies have revealed both oncogenic and tumor suppressive roles for PPARγ (Tontonoz
and Spiegelman, 2008). Heterozygous deletion of PPARγ in mice has demonstrated that it
primarily acts as a tumor suppressor in chemically-induced models of colon (Girnun et al., 2002),
breast, ovarian and skin cancers (Nicol et al., 2004), whereas newly uncovered oncogenic
functions for PPARγ have been reported in bladder cancer using in vitro cell culture models
(Goldstein et al., 2017; Halstead et al., 2017). We hypothesized that PPARγ would promote
ccRCC tumorigenesis due to the fact that its lipid-laden phenotype is tightly linked to cell viability
and proliferation. Our lab previously reported that suppression of the lipid droplet coat protein
perilipin 2 in ccRCC reduces neutral lipid accumulation, engaging the endoplasmic reticulum
stress response and causing tumor regression (Qiu et al., 2015). Additionally, cells defined by
constitutive mTORC1 signaling such as ccRCC (Network, 2013) (Turajlic et al., 2015) require
import of exogenous unsaturated fatty acids during hypoxia to maintain membrane homeostasis
and prevent cell death (Kamphorst et al., 2013; Young et al., 2013). However, our current
understanding of the molecular mediators of lipid uptake and storage in ccRCC is limited.
In this study, we performed loss-of-function experiments to elucidate PPARγ’s role in
ccRCC in established cell lines both in vitro and in vivo. PPARγ deletion in two ccRCC cell lines
affected neither viability, proliferation, migratory capacity in vitro, nor tumor growth in a
subcutaneous xenograft model. Surprisingly, we also show that PPARγ is dispensable for lipid
storage and maintenance of total triglyceride levels in ccRCC cells grown both in vitro and in vivo.
While our data collectively suggest that PPARγ is not required for ccRCC progression, we cannot
exclude a potential role for this nuclear receptor in tumor initiation. The stage-specific
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upregulation of PPARG transcripts in stage I and II kidney tumors (Figure 2.1B-C) is consistent
with PPARγ protein expression patterns in human prostate cancer (Nakamura et al., 2009).
Functionally, this may reflect a role for PPARγ in epithelial-to-mesenchymal transition of renal
epithelium to ccRCC, although this remains to be explored. PPARG expression may also be
inversely related to the differentiation status of tumors, as previously reported in liposarcoma
(Demetri et al., 1999; Tontonoz et al., 1997).
One factor that may influence PPARγ’s function in regulating ccRCC gene expression is
cooperative transcription factor binding. For example, CCAAT-enhancer-binding proteins
(C/EBPs) have been shown to be required for robust PPARγ target gene expression in
adipocytes (Lefterova et al., 2008), yet the C/EBP motif only appeared under ~5% of the binding
sites called in ccRCC (Figure 2.2C). Lack of PPARγ/C/EBP cooperativity may underlie the lack of
“classic” PPARγ target gene expression including CD36, FABP4, and other genes broadly
important in lipid and glucose metabolism (Figure 2.3C) and demonstrate distinct PPARγ action
in ccRCC vs. adipose tissue. Additionally, de novo motif analysis revealed that the retinoic acid
receptor-related orphan receptor alpha (RORα) motif is the second most commonly enriched
motif under PPARγ-RXR-bound DNA in ccRCC (Figure 2.2C). A recent report demonstrated that
RORα reduces PPARγ transcriptional activity via the recruitment of histone deacetylase 3 to
PPARγ target gene promoters in the livers of mice fed HFD (Kim et al., 2017). PPARγ-RORα colocalization in ccRCC and negative regulation of lipid metabolism-related genes would be
consistent with the phenotypes observed in our experiments, as PPARγ depletion did not reduce
triglyceride content or significantly alter expression of de novo lipogenesis enzymes (Figure 2.8).
We considered that compensatory up-regulation of other PPAR family members may
underlie the lack of phenotypes observed in our experiments, however, we determined that
PPARG KO cells do not increase expression of PPARA or PPARD (Figure 2.3D). Indeed,
expression of PPARA, PPARGC1A, and additional genes involved in beta-oxidation of lipids are
highly suppressed in ccRCC relative to healthy renal tubule epithelium (Kang et al., 2015).
Ectopic expression of such factors in ccRCC reduces tumor growth (LaGory et al., 2015), further
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illustrating the importance of reprogramming lipid metabolism from an oxidative to anabolic state
in this tumor type. In conclusion, our investigation of PPARγ in ccRCC led to a novel PPARγ-RXR
cistrome, which shares both similarities and differences with published cistromes in tissues such
as adipocytes and macrophages. Of note, our dataset will be beneficial to researchers studying
cell type-specific functions of PPARγ in cancer as well as the role of other subfamily 1 nuclear
receptors that heterodimerize with RXR in ccRCC. Finally, while PPARγ is expressed in ccRCC
tumors, it does not appear to be necessary for tumor maintenance based on our assays.
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Figure 2.1: PPARγ expression in ccRCC patient samples and cell lines
(A) Frequency of select chromosome 3p gene alterations in ccRCC tumors (cBioPortal). n = 448
patients. (B) PPARG mRNA expression in ccRCC and adjacent healthy kidney tissue from Gumz
Renal microarray dataset. *** (p < 0.001). (C) PPARG mRNA expression in ccRCC and adjacent
healthy kidney tissue from TCGA data set, stratified according to tumor stage. *** (p < 0.001), ** (p <
0.01), n.s. = not significant. (D) RT-qPCR for PPARG expression in eighteen tumor-normal paired
samples. (E) Western blot for PPARγ expression in four tumor-normal paired samples. (F) PPARG
mRNA expression in control renal cell line (HK2, black bar) and ccRCC cell lines (RCC10 through 769P, blue bars). (G) PPARγ protein expression in control renal cell lines (HK2, RPTEC), ccRCC cell lines
(RCC10 through 769-P).
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Figure 2.2: Genome-wide analysis of PPARγ-RXR binding in ccRCC
(A) PPARγ and RXR enrichment at a subset of strong adipocyte binding sites in UMRC2 ccRCC cells
(INS, negative control) assayed by ChIP-qPCR. (B) ChIP-seq tracks of PPARγ WT, PPARγ KD, RXR
and Input, showing binding to enhancer site -12 kb from PDK4. (C) De novo motif analysis of PPARγ
and RXR binding sites. For bioinformatics analyses displayed in C-F, 1031 “high-confidence sites”
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various genomic locations, defined by HOMER annotate peaks. (E) Gene ontology of PPARγ and RXR
binding sites, annotated to nearest gene. 367/1031 genes (36%) were directly shared with human
adipose. Data were compared to published PPARγ ChIP-seq from an adipocyte cell line (Soccio et al.,
2011). Numbers in parenthesis indicate number of genes per category. (F) Gene ontology of PPARγ
and RXR binding sites, annotated to nearest gene. 664/1031 genes (64%) were unique to ccRCC.
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Figure 2.3: Validation of PPARG suppression strategies by shRNA and CRISPR-Cas9
(A) Validation of doxycycline-inducible shRNA system in UMRC2 cells. PPARγ protein levels are
rapidly decreased following addition of doxycycline to media at 1 ug/mL. Doxycycline-inducible SCR
(WT) and PPARG shRNA #3 (KD) cells were collected at the Day 2 timepoint for ChIP-seq experiment.
(B) (Left) Western blot of PPARγ levels following lentiviral infection of UMRC2 cells with several
gRNAs (#1-4) targeting PPARG. (Right) PPARG protein levels following combined lentiviral infection of
UMRC2 cells with gRNAs #1 and #3. Addition of both gRNAs generates nearly complete knockout as
assessed by Western blot, and is referred to throughout the manuscript as “PPARG KO”. (C)
Expression of PPARγ adipocyte target genes FABP4 and CD36 following PPARG KO in UMRC2 cells.
(D) Expression of PPAR family members PPARA and PPARD following PPARG KO in UMRC2 cells.
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Figure 2.5: PPARγ is dispensable for ccRCC viability and proliferation in vitro
(A) Western blot of PPARγ levels in UMRC2 and A498 cells following PPARG KO. (B) Annexin V–PI
flow cytometry plots for UMRC2 and A498 control and PPARG KO cells. (C) Quantification of Annexin
V–PI double-negative population (lower left quadrant) for UMRC2 and A498 control and PPARG KO
cells. (D) Growth curve of UMRC2 cell line measuring proliferation rate of control and PPARG KO cells
over the course of four days. n.s. = not significant. (E) Growth curve of A498 cell line measuring
proliferation rate of control and PPARG KO cells over the course of four days. (F) Growth curve of
UMRC2 tumor spheroids measuring proliferation rate of control and PPARG KO cells over the course
of two weeks. (G) Growth curve of A498 tumor spheroids measuring proliferation rate of control and
PPARG KO cells over the course of two weeks. (H) Representative images of UMRC2 and A498
control and PPARG KO spheroids at indicated timepoints. Scale bar = 100 µm.
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(A) Representative images of UMRC2 and A498 control and PPARG KO cell lines at indicated
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Figure 2.7: PPARγ is dispensable for ccRCC xenograft tumor growth in vivo
(A) Tumor volume measurements for UMRC2 control and PPARG KO subcutaneous xenografts at
indicated timepoints. (B) Tumor weight measurements for UMRC2 control and PPARG KO
subcutaneous xenografts at day 75 post-injection. n.s. = not significant. (C) Representative images of
hematoxylin and eosin (H&E) staining and PPARγ, Ki67 and cleaved caspase-3 immunohistochemistry
from UMRC2 control and PPARG KO subcutaneous xenograft tumors. Scale bar = 100 µm. (D)
Quantification of Ki67-positivity shown in Figure 4C. n.s. = not significant. (E) Quantification of cleaved
caspase-3-positivity shown in Figure 4C. n.s. = not significant.
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Figure 2.8: Lipid storage and triglyceride synthesis occur independently of PPARγ in
ccRCC
(A) Representative images of UMRC2 and A498 control and PPARG KO cells stained with Oil Red O
and counterstained with hematoxylin to visualize nuclei. Scale bar = 100 µm. (B) Quantification of
BODIPY (493/503) staining of UMRC2 and A498 control and PPARG KO cell lines. n.s. = not
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A498 control and PPARG KO cell lines. (D) Triglyceride content of UMRC2 control and PPARG KO
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Chapter 3: Cell-intrinsic tumorigenic functions of PPARγ in
bladder urothelial carcinoma

This chapter is in preparation for submission: Sanchez, DJ, Missiaen, R, Skuli, N, Steger, DJ,
Simon, MC. Cell-intrinsic tumorigenic functions of PPARγ in bladder urothelial carcinoma.
Manuscript in preparation.
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3.1 Abstract
The role of peroxisome proliferator-activated receptor gamma (PPARγ) has been well
characterized in the developmental process of adipogenesis, yet its aberrant expression patterns
and functions in cancer subtypes are less understood. While PPARγ has been recently
demonstrated to play non-cell-autonomous roles in promoting bladder urothelial carcinoma (UC)
progression, its cell-intrinsic, oncogenic functions remain to be fully described. Here, we report
robust expression and nuclear accumulation of PPARγ in 47% of UC patient samples by
immunohistochemistry, exceeding mRNA expression patterns published by The Cancer Genome
Atlas. We use several established human cell lines in in vitro assays to determine the functional
consequence of pharmacological and genetic inhibition of PPARγ in UC. Loss of PPARγ
transcriptional activity reduces proliferation of multiple UC cell lines, most strongly in those
characterized by PPARG genomic amplification or activating mutation of RXRA, the obligate
heterodimer of PPARγ. We show that treatment of UC cells with PPARγ inverse-agonist or
PPARG knockout by CRISPR-Cas9 induces cell cycle arrest in G1 phase. Through genome-wide
approaches including ChIP- and RNA-seq, we define a candidate set of PPARγ-regulated genes
in UC. Collectively, our data indicate that PPARγ promotes UC progression in a subset of
patients, at least in part, through cell-autonomous mechanisms.
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3.2 Introduction
th

Bladder urothelial carcinoma (UC) is the 9 leading cause of cancer worldwide, with an
estimated ~81,000 new cases in 2018 and ~17,000 annual deaths per year in the United States
alone (Siegel Rebecca et al., 2018). Clinically, UC is stratified into non-muscle invasive bladder
cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), both contributing to disease
morbidity and mortality (Robertson et al., 2017). MIBC is currently treated by radical cystectomy
preceded or followed by chemotherapy including methotrexate, vinblastine, doxorubicin, and
cisplatin (Sanli et al., 2017). Recently, large-scale genomic sequencing of hundreds of primary
patient samples has revealed distinct clusters of MIBC, most broadly stratified into luminal and
basal subcategories based on common transcriptional features (Choi et al., 2014a; Sanli et al.,
2017). The identification of molecular signatures and drivers of these programs will pave the way
for improved, targeted therapies, of which there are currently few to treat localized and metastatic
UC.
One transcription factor reported to be a hallmark of luminal MIBC is the peroxisome
proliferator-activated receptor gamma (PPARγ) (Rochel et al., 2019). PPARγ is a member of the
nuclear receptor family of transcription factors, which act as molecular sensors to regulate gene
expression based on environmental and metabolic cues (Ahmadian et al., 2013). PPARγ binds
DNA as a heterodimeric pair with retinoid X receptor (RXR), and exists in complex with corepressor or co-activator proteins depending on activation state. Associations with co-activator or
co-repressor proteins facilitates chromatin remodeling and target gene activation or repression,
respectively (McKenna and O'Malley, 2002). During development, PPARγ and C/EBP
transcription factors induce adipogenesis from mesenchymal progenitor cells (Tontonoz et al.,
1994). In differentiated, post-mitotic adipocytes it regulates the expression of genes involved in
lipid and glucose metabolism, and the expression of endocrine “adipokine” factors which affect
whole-body energy homeostasis (Shapira and Seale, 2019).
Long-term use of certain thiazolidinediones, synthetic agonists of PPARγ used to
manage blood glucose levels in type 2 diabetics, has been associated with increased risk of
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bladder cancer development. Pioglitazone, but not rosiglitazone, has been associated with
bladder cancer risk in some, but not all, population-based cohort studies (Lewis et al., 2011;
Neumann et al., 2012; Tuccori et al., 2016). In a pre-clinical study employing a carcinogeninduced model of bladder cancer, rosiglitazone treatment increased incidence and size of UC in
rats in a dose-dependent manner (Lubet et al., 2008). However, rosiglitazone treatment alone did
not induce UC tumors in this study, suggesting a potential synergistic relationship between
PPARγ activation and carcinogen exposure in UC development in vivo. Nevertheless, these
observations have led our group and others to speculate that PPARγ might be an important factor
in UC development and progression in a subset of patients. Indeed, a number of recent studies
link PPARγ activity to UC, describing its ability to promote disease progression in both cellautonomous (Biton et al., 2014; Goldstein et al., 2017; Halstead et al., 2017; Rochel et al., 2019)
and non-cell-autonomous fashions (Korpal et al., 2017). However, the direct molecular
mechanisms by which PPARγ inhibition reduces tumor growth have not been described, nor have
the downstream mediators of PPARγ-RXR transcriptional activity been defined. In this study, our
objective was to further elucidate the cell-intrinsic role of PPARγ signaling in UC and identify
candidate target genes responsible for UC progression based on genome-wide approaches.
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3.3 Materials and Methods
Primary Patient Samples and Genomics Data
Bladder urothelial carcinoma tissue array containing 60 cases of urothelial carcinoma
plus adjacent normal bladder tissue was purchased from US Biomax, Inc. (cat. BC12011c).
TCGA datasets (Network, 2014; Robertson et al., 2017) were analyzed for PPARG and RXRA
mutational burden, copy number variation, mRNA upregulation, and co-expression patterns using
cBioPortal for Cancer Genomics (Cerami et al., 2012; Gao et al., 2013). The CERES dependency
score (Figure 3.4E) is based on data from a cell depletion assay. A lower score indicates a
higher likelihood that the gene of interest is essential in a given cell line. A score of 0 indicates a
gene is not essential; correspondingly -1 is comparable to the median of all pan-essential genes
(Meyers et al., 2017).

Cell Culture, Plasmids, Lentiviral Production and Transduction
Human UC cell lines (5637, HT-1197, HT-1376, TCCSUP, T24) were purchased from the
American Type Culture Collection (ATCC), with the exception of Cal29 (DSMZ, cat. ACC-515). All
cell lines were cultured in RPMI 1640 medium containing L-glutamine (ThermoFisher Scientific,
cat. 11875-085) supplemented with 10% FBS (Gemini Bio-Products, cat. 900-108). Human
single-guide RNAs (sgRNA) targeting PPARG #6 (cattacgaagacattccatt) and #9
(caactttgggatcagctccg) along with control gRNA targeting mouse Rosa26 locus
(aagatgggcgggagtcttct) were cloned into LentiCRISPRv2 plasmid (Sanjana et al., 2014). Mature
antisense human PPARG shRNA #2 sequence (clone ID: TRCN0000001672) along with
scrambled (SCR) control were cloned into a pLKO lentiviral plasmid. Lentivirus was prepared and
cells were transduced as previously described (Sanchez et al., 2018). All experiments were
performed with cells that survived puromycin selection and displayed knockdown/knockout of
PPARG as assayed by Western blot.

PPARγ Agonists and Inhibitors
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Rosiglitazone (Sigma-Aldrich, cat. R2408) was resuspended in DMSO to create a 1 mM
stock solution and was used at a final concentration of 100 nM in all experiments. The PPARγ
inverse-agonist T0070907 (Santa Cruz Biotechnology, cat. sc-203287) was resuspended in
DMSO to create a 1 mM stock solution and was used at a final concentration of 100 nM in all
experiments. An equivalent volume of DMSO was used as a control for all experiments involving
PPARγ pharmacological agents.

Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (ThermoFisher Scientific, cat. 15596026)
and RNeasy mini kit (Qiagen, cat. 74104). Reverse transcription was performed using HighCapacity RNA-to-cDNA (Applied Biosystems, cat. 4387406). qRT-PCR was performed using
ViiA7 Real-Time PCR system (Applied Biosystems) with TaqMan master mix (Life Technologies).
TaqMan probes were used to quantitate expression of PPARG (cat. Hs01115513_m1), FABP4
(cat. Hs01086177_m1), PLIN2 (cat. Hs00605340_m1), SCD (cat. Hs01682761_m1), LPL (cat.
Hs00173425_m1), PPARA (cat. Hs00947536_m1) and normalized to housekeeping gene TBP
(Hs00427620_m1).	
  

Western Blot and Immunohistochemistry
Western blot was performed as previously described (Sanchez et al., 2018). Primary
antibodies were diluted 1:1000 in 5% w/v nonfat milk (except GAPDH, 1:10,000), and secondary
antibodies were diluted 1:2000 in 5% w/v nonfat milk. PPARγ (cat. 2435), GAPDH (cat. 2118),
and anti-Rabbit IgG, HRP-linked (cat. 7074) antibodies were purchased from Cell Signaling
Technology.
Human bladder cancer tissue array was processed for immunohistochemistry by baking
the slide in a dry oven for 20 minutes at 55°C. Slide was then deparaffinized by incubation in
100% xylene for 15 min, 2X, followed by rehydration in a series of washes from 100% ethanol
(EtOH), 95% EtOH, 70% EtOH, 100% dH2O for 5 min each. Slide was then boiled in antigen
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unmasking solution (1M sodium citrate solution, pH 6.0) for 20 min, left to cool on bench for 20
min, and incubated in dH2O for 20 min for further cooling. Endogenous peroxidase activity was
blocked by transferring slide to 1% H2O2 solution for 30 minutes. Slide was washed in 1X TT
buffer for 5 min, 3X, sample area was outlined with hydrophobic pen, and samples were
incubated in blocking buffer (5% BSA, 2% goat serum diluted in 1X TT buffer) for 1 hr at RT.
Samples were incubated overnight in PPARγ antibody diluted 1:200 in blocking buffer overnight
at 4°C. The following day, slide was washed in 1X TT buffer for 5 min, 3X, and incubated in
secondary antibody (1:200 biotinylated goat anti-Rabbit, diluted in 1X TT) for 1 hr at RT. Slide
was further processed using Vectastain Elite ABC kit (Fisher Scientific, cat. PK6100) according to
the manufacturer’s instructions, and staining was visualized with DAB peroxidase substrate kit
(Vector Laboratories, cat. SK4100). Slide was counterstained with hematoxylin and dehydrated
before coverslipping and imaging.

Chromatin Immunoprecipitation (ChIP) and ChIP-seq
ChIP was performed with whole cell extracts isolated from 5637 parental cells using 2.5
µg PPARγ (Santa Cruz, cat. sc-7196), 2.5 µg RXRα/β/γ (Santa Cruz, cat. sc-774), or 2.5 µg
Normal Rabbit IgG (Cell Signaling Technology, cat. 2729) antibodies for immunoprecipitation (IP).
Briefly, confluent 10 cm dishes of cells were prepared by crosslinking with 1% formaldehyde for
15 minutes at room temperature (RT), and quenched with 125 mM glycine for 5 min at room
temperature. Cells were harvested by scraping and pellets were resuspended in 200 µl SDS lysis
buffer (50 mM HEPES/NaOH pH 7.5, 1% SDS, 10 mM EDTA, 1 mM PMSF, and Roche ULTRA
protease inhibitor cocktail (cat. 05892791001)) on ice for 10 minutes. Sonication was performed
using Bioruptor Pico (Diagenode, cat. B01060010) on high setting for 4 cycles of 30 seconds on,
30 seconds off, followed by centrifugation of lysates to remove cellular debris. 66 µl of sheared
chromatin from each tube was then diluted 10X, with 5% saved as Input DNA and the rest
prepared for either PPARγ, RXR, or IgG IP.
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PPARγ IP, RXR IP, IgG IP and Input libraries were prepared in duplicate from two
independent biological replicates. For ChIP-seq, sequencing data was mapped to the human
genome (GRCh38) using STAR (Dobin et al., 2013) with parameters appropriate for ungapped
alignments. Peaks were called for each sample with input samples as background by HOMER
(Heinz et al., 2010). HOMER was also used for differential peak calling (PPARγ vs. Input and
RXR vs. Input) and to annotate peaks to proximal genes as described in Ensembl v85
(http://www.ensembl.org/index.html). Motif enrichment analysis was performed using HOMER
against the standard list of known motifs; de novo motif discovery included consideration of
lengths 8,10,12,15,18 bp. For bioinformatics analyses displayed in Figure 3.6C-D, “highconfidence sites” were defined by the following criteria: peak score ≥ 10 (≥ 1 read per million) and
RXR peak called with strict overlap. Gene ontology was performed using Metascape
(metascape.org).

RNA-seq
Total RNA was isolated from four technical replicates of 5637 control, 100 nM T0070907treated, PPARG sgRNA 6, and PPARG sgRNA 9 cell lines as described above. NEBNext Ultra II
RNA Library Prep Kit for Ilumina was used for preparing ~250-300 bp insert cDNA, nondirectional libraries according to manufacturer’s instructions at Novogene Corporation
(Sacramento, CA). Libraries were sequenced using the Ilumina platform with paired-end 150 bp
sequencing at 20M raw reads/sample at Novogene. Raw sequence files (fastq) for 16 samples
were mapped using Salmon (Patro et al., 2017) against the human transcripts described in
GENCODE (version 28, built on the human genome GRCh38.p12). Transcript counts were
summarized to the gene level using tximport (Soneson et al., 2015), and normalized and tested
for differential expression using DESeq2 (Love et al., 2014). Statistics for each contrast of interest
were exported for further analysis. Genes used for gene ontology met the following criteria:
significantly up- or down-regulated by inverse-agonist or CRISPR treatment at least 1.5-fold with
padj < 0.05. Gene ontology was performed using Metascape (metascape.org).
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Annexin V-PI Apoptosis Assay
5,000 cells of each cell line were plated in triplicate on 6-well plates. Cells were treated
for 8 days with media containing DMSO or 100 nM T0070907, and then prepared using the
FITC–Annexin V, PI Kit (BD Biosciences, cat. 556547) according to the manufacturer’s
instructions. Flow cytometry was performed using the BD Accuri C6 instrument, with viable cells
represented as the double-negative population.

Proliferation Assay
25,000 cells of control gRNA, PPARG sgRNA #6, or PPARG sgRNA #9 UC cell lines
were plated in triplicate on 6-well plates. The following day (represented as Day 0), cells were
trypsinized and counted using the Countess Automated Cell Counter (Invitrogen, cat. C10281),
as per the manufacturer's instructions with Trypan blue. Cells were then counted again at the
indicated timepoints, and fresh media was added every two days.

Clonogenic Growth Assay
5,000 cells of each cell line were plated in triplicate on 6-well plates. The next day, media
containing either 100 nM T0070907 or an equivalent volume of DMSO was added to the wells in
triplicate. UC cells were treated with DMSO or T0070907 for 9 days (with the exception of T24, 5
days) with fresh medium supplied every 2 days. At the end of the experiment, cells were washed
in PBS and stained with crystal violet solution (0.5% crystal violet in 20% methanol) for 10
minutes. Plates were then washed twice with PBS and allowed to dry before imaging.
Quantitation was performed by adding 500 µL methanol to dry wells and incubating at RT with
rocking for 20 minutes. Absorbance was read using a spectrophotometer at 570 nm, and data are
represented as fold change relative to DMSO readings.

Cell Cycle Analysis
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5,000 cells of the 5637 cell line were plated on 6-well plates. The following day, cells
were serum starved for 24 hours to synchronize the population, after which media containing
DMSO and 100 nM T0070907 were added to triplicate wells. Cells were harvested after 5 days of
drug treatment, fixed using ice-cold 70% ethanol, and stored at -20°C for 2 hours. Following
centrifugation and removal of ethanol, cells were washed twice in FACS buffer (PBS containing
2% FBS and 1 mM EDTA). For dual Ki67/PI staining to determine non-proliferative (G0
population): samples were resuspended in 200 µL FACS buffer and stained for 30 minutes at RT
in the dark with Ki67-FITC monoclonal antibody (SolA15) (Life Technologies, cat. 11-5698-82) at
1:100. Cells were then washed twice with FACS buffer and resuspended in 500 µL PI staining
solution (PBS containing 50 µg/mL PI, 100 µg/mL RNAse A and 2 mM MgCl2). Cells were
strained through 40 µm filters and incubated at RT in the dark for 20 minutes before analysis by
flow cytometry. For analysis of the cell cycle phases, cells were stained with PI antibody only.

Adipogenesis Assay
250,000 NIH-3T3 cells (ATCC) were infected with MSCV-retroviral empty vector or vector
containing PPARG cDNA resistant to shRNA #2 on 10 cm dishes. When cells were confluent,
induction medium was added to the plates for 48 hours (DMEM containing 10% FBS
supplemented with 125 nM indomethacin, 0.5 mM isobutylmethylxanthine (IBMX), 1 mM
dexamethasone, 20 nM insulin, and 1 µM rosiglitazone). After 48 hours, medium was changed to
DMEM containing 10% FBS supplemented with 20 nM insulin and 1 µM rosiglitazone. Medium
was changed every 2 days until plates were harvested on day 10 after induction and stained with
oil red o to visualize adipogenesis. Oil red o staining was performed as previously described
(Sanchez et al., 2018).

Statistics
Statistical analyses were performed in Microsoft Excel using Student’s two-tailed,
unpaired t-test. Data are presented as mean ± SD of at least three independent experiments.
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Statistical significance was defined as *** (p < 0.001), ** (p < 0.01), * (p < 0.05), n.s. = not
significant.

3.4 Results
3.4.a Characterization of PPARγ expression in bladder urothelial carcinoma
Genomic sequencing data available from The Cancer Genome Atlas (TCGA) revealed
that 21% of UC tumors have genomic amplification and/or mRNA upregulation of PPARG, and
that 11-14% display genomic amplification and/or activating mutation in RXRA, the obligate
heterodimer of PPARγ, in a largely mutually-exclusive pattern (Figure 3.1A). To validate that the
effects on PPARG mRNA abundance translated to protein expression, we performed
immunohistochemistry for PPARγ on 60 independent UC patient samples from a commercially
available tissue array (Figure 3.1B). Surprisingly, our analysis revealed that nearly 50% of UC
tissues stained positive for PPARγ nuclear accumulation, while normal bladder epithelium was
entirely negative (Figure 3.1C-D). Consistent with the pattern observed in primary patient
samples, analysis of Cancer Cell Line Encyclopedia (CCLE) data demonstrated that across all
tumor types, PPARG mRNA expression was significantly elevated in human cancer cell lines
derived from the urinary tract (Figure 3.1E).

3.4.b Pharmacological inhibition of PPARγ reduces growth of a subset of bladder
urothelial carcinoma cell lines in vitro
In agreement with previously published data (Biton et al., 2014; Goldstein et al., 2017),
treatment of a number of human UC cell lines with the PPARγ inverse agonist, T0070907,
decreased clonogenic growth over the course of six to ten days (Figure 3.2A-B). We confirmed
that treatment with T0070907 affected gene expression at the concentration administered by
assessing the expression of two PPARγ target genes, PLIN2 and FABP4, by qPCR in the 5637
cell line (Figure 3.3A). The cell lines which displayed the largest decrease in proliferation, 5637
and HT-1197, are notable in that they display PPARG genomic amplification and a RXRα
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p.S427F predicted activating mutation (Halstead et al., 2017), respectively. We next performed
flow cytometry-based, Annexin V-propidium iodide (PI) staining to determine the effect of the
PPARγ inverse-agonist on cell viability. Long-term treatment of six UC cell lines with T0070907
did not decrease viability of cells relative to control (Figure 3.2C), suggesting that reduced cell
number following pharmacological inhibition of PPARγ may result from cell cycle arrest rather
than induction of cell death (Biton et al., 2014). To test this, we performed PI staining on 5637
cells treated with T0070907 for 5 days to analyze the percentage of cells within each phase of the
cell cycle. Treatment with PPARγ inverse-agonist significantly increased the percentage of cells
in G1 phase and reduced the G2/M phase population relative to control (Figure 3.2D, Figure
3.3B). Additionally, we determined that T0070907 increased the percentage of cells in G0 phase
relative to control 4-fold (Figure 3.2E) after seven days of treatment. These results suggest that
pharmacological inhibition of PPARγ reduces cell cycle progression in a subset of UC.

3.4.c Genetic inhibition of PPARγ reduces growth of several bladder urothelial carcinoma
cell lines in vitro
To validate the effects observed by pharmacological inhibition of PPARγ, we next
depleted PPARγ protein from the panel of sensitive UC cell lines using two independent sgRNA
using the CRISPR-Cas9 gene editing system. PPARγ depletion via CRISPR also inhibited the
proliferation of these UC cell lines in vitro (Figure 3.4A-B, Figure 3.5A), in a similar manner to
that observed through pharmacological PPARγ inhibition. Indeed, PPARG KO also resulted in a
block in cell cycle progression in the 5637 cell line (Figure 3.4C-D), increasing the percentage of
cells in G1 and lowering the G2/M phase population relative to control knockout. Furthermore, we
employed an shRNA-resistant PPARG cDNA to validate the effects of PPARγ depletion on cell
growth in UC (Figure 3.5B-C), and we confirmed functionality of the shRNA-resistant PPARG
cDNA by its ability to induce adipogenesis in NIH-3T3 cells when cultured in the presence of
adipogenic stimuli (Figure 3.5D). These data confirm the sensitivity of a subset of urinary tract-
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derived tumors to PPARG knockdown in vitro, as predicted from CCLE Achilles heel shRNA and
CRISPR screens (Figure 3.4E) (Barretina et al., 2012; Meyers et al., 2017).

3.4.d Genome-wide analysis of PPARγ-RXR binding and gene regulation in UC
To investigate PPARγ occupancy genome-wide in UC, we performed chromatin
immunoprecipitation followed by deep sequencing (ChIP-seq) in the 5637 cell line for PPARγ,
RXR, and IgG and Input controls (Figure 3.6A, pre-sequencing ChIP validation shown in Figure
3.7A). Additionally, we confirmed PPARγ and RXR binding at several strong binding sites by
ChIP-qPCR (Figure 3.7B-C, Table 1). De novo motif analysis revealed that the majority of
PPARγ-RXR binding in UC cells occurs at the direct repeat 1 (DR1) nuclear receptor motif
(Figure 3.6B), consistent with binding patterns in other cell types including adipocytes,
macrophages (Lefterova et al., 2010), lung adenocarcinoma (Srivastava et al., 2014), and clear
cell renal cell carcinoma (ccRCC) (Sanchez et al., 2018). A previous report demonstrated that the
transcription factors FOXA1, GATA3, and PPARγ are major molecular drivers of the luminal
subtype of UC (Warrick et al., 2016), but did not investigate whether these proteins work
coordinately based on proximal DNA binding to promote a luminal vs. basal state. Our data
indicate that FOXA1, GATA3, and PPARγ likely regulate distinct genes in UC, based on the fact
that neither FOXA1 nor GATA3 motifs were enriched at PPARγ-RXR binding sites (Figure 3.6B).
In agreement with this, the DR1 motif was not enriched under FOXA1 occupied regions in the
luminal RT4 bladder cancer cell line (Warrick et al., 2016). PPARγ-RXR heterodimers were
predominantly located in intergenic and intronic regions of the genome at 46.08% of sites and
42.37% of sites, respectively (Figure 3.6C). To begin to elucidate the transcriptional programs
regulated by PPARγ in UC, we annotated PPARγ-RXR binding sites to the nearest gene and
performed gene ontology (GO) for 2581 genes. We found that GO pathways involved in
migration, adhesion, and regulation of transmembrane receptor tyrosine kinase signaling were
most highly represented among this gene set (Figure 3.6D).

69

	
  

To determine the effects of PPARγ inhibition on gene expression, we performed RNAseq in the 5637 cell line with four experimental conditions involving either inverse-agonist
treatment or gene knockout by two PPARG sgRNA (Figure 3.6E). As the knockout of PPARG
was incomplete at the protein level for sgRNA 9 (Figure 3.6E), we proceeded to narrow our
targets of interest based on overlap between inhibitor treatment and PPARG KO by sgRNA 6.
Significantly altered genes by both PPARG CRISPR knockout and inhibitor were enriched in
pathways related to inflammatory response (Figure 3.6F), including leukocyte chemotaxis,
response to tumor necrosis factor, and response to lipopolysaccharide. Importantly, we confirmed
that six chemokines whose expression increased following PPARγ inhibition (Figure 3.8A) did
not have PPARγ-RXR binding sites within 200 kb of the TSS (data not shown). These results
suggest that the inflammatory response inhibited by active PPARγ signaling is likely mediated by
an independent transcriptional program such as NF-κB in UC. However, this is unlikely to occur
through direct transrepression of NF-κB targets by PPARγ, as was previously suggested (Korpal
et al., 2017).
We predict that PPARγ targets of interest in regulating UC proliferation fall into a list of 30
protein-coding genes significantly downregulated at least 1.5-fold (padj < 0.05) by both inhibitor
treatment and PPARG KO by sgRNA 6 (Figure 3.9C). Of the 30 genes, 7 had a significant
positive association with PPARG expression in RNA-seq data from 126 primary bladder urothelial
carcinoma samples (Network, 2014; Robertson et al., 2017). One of the most downregulated
genes among all groups in our dataset was sonic hedgehog (SHH), a regulator of embryonic
development and maintenance of tissue polarity (Rimkus et al., 2016; Villavicencio et al., 2000)
(Figure 3.8B). PPARγ-RXR heterodimers bind several locations up and downstream of SHH
within a 200 kb window (Figure 3.8C). Functionally, SHH-expressing cells were shown to give
rise to MIBC in a carcinogen-induced mouse model (Shin et al., 2014a), but its connection to
PPARγ signaling has not yet been described. Another gene of interest is proline-rich 15 (PRR15),
also significantly downregulated following PPARγ inhibition in all three experimental conditions
with two PPARγ-RXR binding sites within a 200 kb window of the gene (Figure 3.8D-E).
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Importantly, PRR15 exhibited a strong positive correlation with PPARG expression in primary
patient samples according to TCGA data (Figure 3.8F). Although PRR15 function is currently
unknown, high mRNA expression was observed in murine and human colorectal carcinoma
samples bearing mutations in the APC gene (Meunier et al., 2011). PRR15 expression in tumors
from Apc

Min/+

mice co-localized with Ki67 and histone H3 positivity, and elevated levels were

associated with advanced tumor stage in human colorectal cancer. Furthermore, another recent
study demonstrated that PRR15 is required for ovine and human trophoblast viability and survival
(Gates et al., 2017). These data lead us to speculate that genes such as SHH and PRR15 are
associated with PPARγ-dependent proliferation and cell cycle progression in bladder urothelial
carcinoma.

3.5 Discussion
Active PPARγ-RXR signaling has been implicated as a molecular signature of luminal
MIBC, yet the cell-autonomous mechanisms by which PPARγ contributes to UC growth are
incompletely understood. In this study, we confirmed that treatment of UC cell lines with PPARγ
inverse-agonist T0070907 reduced growth in vitro as previously reported (Goldstein et al., 2017),
and demonstrated that pharmacological inhibition of PPARγ results in reduced cell cycle
progression rather than induction of apoptosis. The block in the G1 phase of the cell cycle
observed following treatment with inverse-agonist was also replicated by genetic knockout of
PPARG by CRISPR-Cas9. To further elucidate the effects of genetic and pharmacological
inhibition of PPARγ signaling in UC, we performed ChIP- and RNA-seq to identify commonly
deregulated pathways. Our findings corroborate recently published data showing an inverse
correlation between PPARγ activity and immune infiltration in UC (Korpal et al., 2017), and also
reveal novel PPARγ-RXR transcriptional targets which may be responsible for promoting growth
in UC.
Interestingly, lipid and glucose metabolism-related pathways were not among the most
highly enriched pathways in our ChIP-seq dataset, suggesting that the PPARγ-RXR cistrome is
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distinct in UC relative to other cell types including adipocytes and ccRCC (Lefterova et al., 2008;
Sanchez et al., 2018). However, analyses of downregulated genes comparing control to either
PPARγ inhibitor-treated or PPARG sgRNA 6-treated cells suggest that some “canonical” targets
are affected in UC, as evidenced by downregulation of several targets within the KEGG
hsa03320: PPAR signaling pathway (FABP5, PLIN2, LPL, SCD) by both manipulations (Figure
3.9C). The absence of widespread alterations in gene expression involved in lipid and glucose
metabolism pathways may be explained by the lack of C/EBP transcription factor co-occupancy
with PPARγ in this cistrome. We hypothesize that the targets most important for UC proliferation
are related to extracellular matrix organization (matrisome associated), adhesion, and cytokinemediated signaling pathways (Figure 3.6D-F). Future studies performing ChIP-seq in primary
urothelial carcinoma tissue would be beneficial to validate the genomic occupancy patterns
observed in the 5637 cell line, and to further correlate genomic binding with PPARγ-responsive
genes in vivo.
Based on our ChIP- and RNA-seq data, we propose SHH as a novel target gene of
PPARγ in UC. Briefly, SHH is a signaling effector that binds extracellularly to the transmembrane
receptor Patched (PTCH). The PTCH-SHH interaction inactivates the 7-pass transmembrane
receptor Smoothened, which allows for the transcription factor GLI1 to translocate to the nucleus
and regulate genes involved in proliferation and stem cell self-renewal (Rimkus et al., 2016). SHH
expression has a weak, yet statistically significant positive association with PPARG expression in
primary patient samples according to TCGA data, and treatment of the 5637 cell line with the
PPARγ agonist rosiglitazone increased expression of this gene 4-fold relative to control. Our gainand loss-of-function experiments suggest that SHH is a direct target gene of PPARγ in the 5637
in vitro cell culture model of UC (Figure 3.9A-B). The varied levels of natural endogenous ligands
of PPARγ in vitro and in vivo certainly affect gene expression, and is an important consideration
when trying to identify targets likely to be most relevant to the human disease. Functionally, SHH
has been implicated in normal bladder development and in the maintenance of bladder cancer
stemness (Syed et al., 2016). SHH positivity is also associated with the luminal-papillary subclass
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of MIBC, the same as PPARγ (Robertson et al., 2017). However, the role of the SHH pathway in
UC is controversial, with reports indicating both pro- (Islam et al., 2016; Nedjadi et al., 2018) and
anti-tumorigenic (Shin et al., 2014b) roles in UC initiation and progression. The relationship
between PPARγ signaling, SHH expression, and UC proliferation remains to be further clarified.
Another putative PPARγ target of interest based on our ChIP-seq, RNA-seq, and gene
expression data from primary samples is PRR15. PRR15 knockdown reduced the expression of a
number of pro-proliferative cell cycle genes including CCND1 and CDK6 and increased the
expression of anti-proliferative genes CCNG2 and CDKN1A in a human trophoblast cell line
(Gates et al., 2017). However, its role and expression patterns in UC have not been previously
described. In conclusion, our study supports a cell-autonomous, pro-oncogenic role for PPARγ
signaling in luminal bladder urothelial carcinoma and provides a candidate list of target genes
responsible for these phenotypes from the intersection of in vitro genome-wide approaches and in
vivo primary patient sequencing data.
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Figure 3.1 – Characterization of PPARγ expression in bladder urothelial carcinoma (UC)
(A) Frequency of copy number, mutational, and gene expression alterations in PPARG and RXRA
from primary UC tumors. n = 529 patients (cBioPortal). (B) Immunostaining of PPARγ in tissue array of
60 primary UC tumors and healthy bladder tissue. (C) High-magnification images of PPARγ staining in
primary UC tumors and healthy bladder tissue. Scale bar = 100 µm. (D) Quantification of PPARγ
nuclear expression in primary UC tumors. (E) PPARG mRNA expression patterns across human
cancer cell lines documented by the Cancer Cell Line Encyclopedia (CCLE).
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Figure 3.2 – Pharmacological inhibition of PPARγ reduces growth of a subset of UC cell
lines in vitro
(A) Clonogenic growth of UC cell lines treated with DMSO or 100 nM T0070907 in long-term culture
assayed by crystal violet staining. (B) Quantification of crystal violet staining in panel (A), depicted as
relative absorbance compared to DMSO. ** (p < 0.01), * (p < 0.05), n.s. = not significant. (C) Annexin
V–PI double-negative population of UC cell lines treated with DMSO or 100 nM T0070907 in long-term
culture, determined by flow cytometry. ** (p < 0.01), * (p < 0.05), n.s. = not significant. (D) Percentage
of 5637 cells in each phase of the cell cycle following DMSO or 100 nM T0070907 treatment,
determined by flow cytometry staining of propidium iodide. *** (p < 0.001), ** (p < 0.01), n.s. = not
significant. (E) Percentage of Ki67-/PI+ 5637 cells following DMSO or 100 nM T0070907 treatment,
determined by flow cytometry. ** (p < 0.01).

75

	
  

A

5637 cell line

Relative Expression

1.2

0.8

0.4

0.0

PLIN2

FABP4

DMSO
100 nM T0070907

B

DMSO

Propidium Iodide

100 nM T0070907

Propidium Iodide
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progression
(A) qPCR for PPARγ target genes PLIN2 and FABP4 following 48 hrs of DMSO or 100 nM T0070907
treatment in 5637 cells. (B) Representative flow cytometry plots of data displayed in Figure 3.2D.
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Figure 3.9 – Downregulated RNA-seq targets from the 5637 cell line
(A) Co-expression data for PPARG and SHH in UC tumors from the TCGA provisional dataset
(cBioPortal). (B) SHH gene expression following 100 nM Rosiglitazone or T0070907 treatment, relative
to DMSO. (C) Gene expression changes for 30 downregulated genes in both 100 nM T0070907 or
PPARG sgRNA 6, relative to control. Red highlighting denotes significant positive association with
PPARG mRNA expression in primary UC tumors.
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Table 1 – Primers used in ChIP-qPCR experiments
Gene

Forward Primer

Reverse Primer

PDK4

GCAGAGTCAACAAGGGGAAG

ACTAGATGCCTGGGAGCTGA

FABP4

GTCCCTCTGGGGTTTTGATT

CATTTGCAGAGTTTGGCAAG

CD36

GTCATTCCATCAGCATGAGC

GGTTGGGATGAGATGAAAGC

FBXW4

TGAAATCAGAGCCACCACCT

TCCTTGCACCATTCACTTTG

PLIN1

GCAGAATGTGGGTGAGAGGT

GAACTCTATGCCCTGCAAGC

SYN2

CTGGTGAGGGGTCACACTCT

GAAGGGAGAACTTGGGGTCT

CPT1A

CACGTGACGGCTGAGAAAAG

CGGGTGGAACAGGATCCGAG

ANGPTL4

AACCTGACAGGCAATGACGC

GCCTGGCTCTATGTAAGGCAA

TRIL

GGCATTCATGGAAGCCACAC

CCAGAGTGACCAGGAAGACG

ECH1

CAAAGCGGTCAAAGAGCAGG

CAGACAGCGCCTCGGTG

SQSTM1

GCCTCCAGGTAAGAGGTCAC

CCCATGACCGCTGTCGTAAT

SLC25A42

GACCGCACAGGCAGTTTTC

CTGCTCTGAGATGTCACCTGG

DLG4

TAGGGGAAAGGTCACCGCTT

GAAGGGACTTCCGCTGTGTC

PDK2
INS

GTGCCCTTTGCTCCACTTCA
GCCCACCCTCTGATGTATCT

GGCTGCTCAACAACCCTAGA
AAAGTGACCAGCTCCCTGTG

SOX4 -22kb

TCCTGCCTGATAATGGGTGAG

CACGCTAAGCAGGAAGGAAA

CASC15 intronic

CGCACACCTGATTCACACAT

CAAAGGGCAAATGCCAGTCT

CDKAL1 intronic #1

CACAGGCTGACTAGGACCAA

TGAACTACAGCTGAGGAAGCA

CDKAL1 intronic #2

CACAAGGGCATAAAGCCAGT

GGTCATAGGATGGGCTGGAT

HS1BP3-IT1

CTTGACCCTTCCTCCCACAA

TACACAGTTCCCTGCACACA

RXRA

GGCAAGTCAGGGCAGGTG

CTGGGATCGGCGTGACTC

ARHGAP23

TTGTCAGGCGGGAGTCTCTA

CAGGCCTCTTCCACCCTTT

CDKAL1 intronic #3

TGTGAACATCCTGGCTCAGT

CACAGGTGTGGCAAAGTTGA
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Chapter 4: Conclusions and Future Directions
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
84

	
  

4.1 Summary of thesis research
In my thesis research, I sought to address the following questions related to the function
of the nuclear receptor PPARγ in clear cell renal cell carcinoma (ccRCC) and bladder urothelial
carcinoma (UC). 1) How does PPARγ-RXR genomic occupancy differ between lineages? 2) Does
PPARγ primarily regulate genes involved in lipid and glucose metabolism in these cancer
subtypes, or are there unique targets that contribute to the cell-type specific functions of this
nuclear receptor? 3) Does inhibiting PPARγ activity, either pharmacologically or genetically, affect
tumor growth of ccRCC and UC? If so, what are the molecular mechanisms responsible for this
dependency?
Based on our ChIP-seq results in both ccRCC and UC, we determined that PPARγ
binding occurs at a majority of sites in both cancers at the canonical PPAR nuclear receptor motif
AGGTCA(N)AGGTCA, known as the direct repeat 1 (DR1). More than 50% of the peaks called in
both our ccRCC and UC datasets contained this motif (Figure 2.2C, Figure 3.6C). In ccRCC,
stratification of PPARγ-RXR peaks into “adipose-shared” and “ccRCC-specific” sites revealed
~36% similarity of binding at adipocyte locations (Soccio et al., 2011). Another striking similarity
between the ccRCC and UC cistromes is the lack of the CCAAT-enhancer-binding protein
(C/EBP) motif at PPARγ-RXR sites in these cancers. Even though our RNA-seq data using
PPARG shRNA in the ccRCC model was largely unusable due to off-target effects, we did not
see any evidence of downregulation of lipid or glucose metabolism-related targets in this cancer
(data not shown). In UC, PPARγ inhibition largely altered the expression of genes involved in
inflammatory responses, migration, and adhesion (Figure 3.6F). We speculate that these results
are consistent with the lack of C/EBP transcription factor co-occupancy at a number of adiposerelated sites and may help to explain the tissue-specific gene expression patterns observed.
Functionally, we determined that PPARγ is dispensable for ccRCC progression but
required for growth in a subset of luminal MIBC tumors. Based on our in vitro data, we also
predict that UC tumors with copy-number amplification of the PPARG gene, or activating point
mutation in RXRA may be particularly dependent on this nuclear receptor for optimal growth.
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Mechanistically, PPARG knockout by CRISPR-Cas9 or treatment with the PPARγ inverse-agonist
T0070907 resulted in a block in the G1 phase of the cell cycle, and also increased the percentage
of non-cycling cells (G0) four-fold relative to control (Figure 3.2-3.4). We hypothesize that PPARγ
target genes such as sonic hedgehog (SHH) and proline-rich 15 (PRR15) may be important
molecular mediators of this dependency (see below). These targets were chosen based on our
ChIP- and RNA-seq data, as well as publicly available gene expression data from primary human
UC samples. These target genes will be the subject of our future investigations.

4.2 Future directions for ccRCC project
Identification of HIF target genes involved in tumor growth and lipid metabolism
Our initial rationale and interest in exploring the role of PPARγ in ccRCC was rooted in
trying to identify factors that might affect lipid uptake, storage, and/or synthesis in this disease. As
described in Chapters 1 and 2, ccRCC is a cancer subtype typified by robustly lipid-laden cells.
Major transcriptional regulators of this process are the hypoxia-inducible factors (HIFs), although
the downstream target genes directly connected with lipid metabolism have not been entirely
defined. The positive relationship between HIF activity and lipid accumulation in ccRCC was
identified during von Hippel-Lindau (pVHL) reconstitution experiments, which entirely reversed
the phenotype in cell culture models (Du et al., 2017). At the time of my preliminary exam, I
hypothesized that PPARγ was a direct transcriptional target of HIF-1α, similarly to what had been
reported in the context of cardiomyocytes following ischemic injury (Krishnan et al., 2009).
However, given the results presented in Chapter 2, we determined that PPARγ was entirely
dispensable for lipid storage and triglyceride synthesis in both in vitro and in vivo models of
ccRCC (Figure 2.8). We also determined that PPARγ protein levels were not altered by shRNA
knockdown of either HIF1A or HIF2A in ccRCC (data not shown).
An important future line of investigation will be identifying the direct transcriptional targets
of the HIFs involved in lipid metabolism in ccRCC. Previously, our lab demonstrated that the HIF2α target gene PLIN2 is an important regulator of neutral lipid storage and tumor growth in this
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cancer (Qiu et al., 2015). However, ectopic PLIN2 expression in the context of HIF-2α-deficiency
only rescued xenograft tumor growth by ~20%. This indicates that additional HIF-2α target genes
are required for robust tumor growth. A previously published ChIP-seq dataset of both HIF-2α
and HIF-1β (ARNT) in the 786-O cell line will be useful a useful tool to determine which targets
explain the pVHL add-back data (Schödel et al., 2012). However, the 786-O cell culture model is
still limited in that it does not express HIF-1α, which is important in early disease development
even though it is commonly lost as disease progresses (Gordan et al., 2008; Kaku et al., 2004;
Rankin et al., 2006). Performing ChIP-seq on primary ccRCC tumors with a combination of HIF1α, HIF-2α, and HIF-1β will allow researchers to compare genomic occupancy of these
transcription factors in cell culture models to primary tissues, which could further reveal important
targets and allow us to determine the fidelity of our in vitro models to the human disease. These
data could also be combined with RNA-seq data from 480 primary human tumors and 69 healthy
kidney tissue samples available from The Cancer Genome Atlas to validate functional binding
near genes of interest (Network, 2013).
As described in Chapter 2, we determined that PPARG knockout was dispensable for
ccRCC tumor growth in several established cell culture models in vitro and xenograft tumor
growth in vivo. Given these results, I do not think it is worthwhile to continue with this line of
investigation in genetically-engineered mouse models of ccRCC, should they become available in
the near future (Chapter 1.2.b).

4.3 Future directions for UC project
PPARG KO in mouse models of UC
To definitively connect PPARγ activity to UC development and progression in an
autochthonous in vivo model, it would be useful to cross PPARG

fl/fl

mice with Upk2-Cre

transgenic mice. These have the mouse uroplakin 2 (Upk2) gene promoter driving Crerecombinase expression in the bladder urothelium, and are useful for studies of normal urothelial
function and cancers of the bladder (de la Peña et al., 2011). PPARG KO experiments could be
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performed using both genetic and carcinogen-induced mouse models of UC. Upk2-Cre
inactivation of the tumor suppressors p53 and Rb by SV40 large T-antigen expression results in
carcinoma in situ with low copy number, whereas high copy number of SV40 results in invasive
and metastatic UC (Zhang et al., 1999). Given our in vitro results, we predict that PPARG KO in
this model would delay tumor growth relative to control. Alternatively, the delivery of the
carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in the drinking water of rodents has
been shown to specifically induce urinary bladder tumors, 95% of which are transitional cell
carcinoma with morphological characteristics similar to those seen clinically in humans
(FUKUSHIMA et al., 1976). We predict that PPARG KO in this model would delay tumor onset
and/or reduce the size of tumors in this experimental setup, inverse to the results described by
dual BBN/TZD treatment (Lubet et al., 2008). One proposed explanation of the effect of PPARγ
deletion on reduced tumorigenesis would be the downregulation of SHH signaling, since SHHexpressing cells have been identified as a cell-of-origin in a BBN-induced MIBC model (Shin et
al., 2014a).

Mechanism of PPARγ-dependent and PPARγ-independent UC progression, and therapeutic
implications
Since PPARγ is a critical factor involved in proliferation and cell cycle progression of a
subset of UC cell lines, it will be important to further delineate the mechanism of action of PPARγ
dependency in these tumors. We speculate that PPARγ transcriptional targets SHH and PRR15
may be involved in promoting luminal UC, given the role of these targets in development and in
other cancer models (Chapter 3.4.d-3.5), and their co-expression status with PPARG in primary
human UC tumors. Experimentally, SHH or PRR15 reconstitution in PPARG-deficient UC cells
would allow us to determine what percentage of the growth defect is due to the loss of these
genes, either alone or in combination.
Although our data suggest that PPARγ is required for growth in a subset of UC that could
easily be assessed by genomic profiling, the direct use of PPARγ inhibitors would prove
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challenging due to adverse effects on adipose tissue and whole-body metabolism. PPARγ is
required for the development and maintenance of white and brown adipose tissue, and knockout
of this factor in a fat-specific manner results in hepatosteatosis, elevated blood glucose levels,
and insulin resistance	
  (He et al., 2003; Imai et al., 2004; Wang et al., 2013). Additionally,
heterozygous mutation of PPARG has been linked to familial partial lipodystrophy, which is
associated with the loss of subcutaneous fat from the extremities and provides further evidence of
the necessity of PPARγ activity in maintaining metabolic homeostasis (Agarwal and Garg, 2002).
Although pharmacological inhibition of PPARγ is unlikely to produce as severe of a phenotype as
genetic deletion in the entire adipose lineage, it is still reasonable to question whether the PPARγ
pathway should be targeted for therapeutic benefit in cancer. I suggest the following to
circumvent these challenges: 1) Use PPARG and/or RXRA amplification/mutational status as a
biomarker for targeted therapy, particularly to assess likelihood of response to immunotherapy
(Korpal et al., 2017) 2) Pharmacologically inhibit the downstream target genes of PPARγ-RXR
rather than these nuclear receptors directly.
It is also important to note that PPARγ is absent at the protein level from 53% of all
primary UC samples tested in our tissue array (Figure 3.1B-D). The following could explain these
data and inform rational treatment strategy in the future: 1) PPARγ activity is required for disease
initiation but expression is lost as the cancer progresses. 2) The PPARγ-negative samples
represent a “basal” subtype of MIBC, which is characterized by expression of the biomarkers
TP63 (p63), STAT3, and EGFR. This signature is distinct from the “luminal” subtype which is
characterized by expression of the biomarkers ESR1, FGFR3, and the transcription factors
FOXA1, GATA3, and PPARγ (Choi et al., 2014a; Warrick et al., 2016). Similarly to what we have
described for PPARγ, EGFR amplification occurs in a subset of basal MIBCs, and cell lines with
amplified EGFR are highly sensitive to EGFR inhibitors (Black et al., 2008; Shrader et al., 2007).	
  
Immunostaining for these various biomarkers in primary patient samples could help clinicians
determine which samples are likely to respond to targeted therapy, immunotherapy, and predict
prognosis given the aggressiveness of the subtype. A deeper understanding of the role of
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amplified/signature proteins which characterize each subtype of MIBC will guide the development
of UC-specific therapeutics that will hopefully be more precise, less toxic, and less invasive then
the current standard of care.
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